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A B S T R A C T
Background
Antidepressants may be useful in the treatment of abnormal crying associated with stroke. This is an update of a Cochrane Review first
published in 2004 and last updated in 2010.
Objectives
To determine whether pharmaceutical treatment reduces the frequency of emotional displays in people with emotionalism after stroke.
Search methods
We searched the trial register of Cochrane Stroke (last searched May 2018). In addition, we searched the Cochrane Central Register of
Controlled Trials (CENTRAL; to May 2018), MEDLINE (1966 to 14 May 2018), Embase (1980 to 14 May 2018), CINAHL (1982
to 14 May 2018), PsycINFO (1967 to 14 May 2018), BIOSIS Previews (2002 to 14 May 2018), Web of Science (2002 to 14 May
2018), WHO ICTRP (to 14 May 2018), ClinicalTrials.gov (to 14 May 2018), and ProQuest Dissertations and Theses Database (to
14 May 2018).
Selection criteria
Randomised controlled trials (RCTs) and quasi-RCTs comparing psychotropic medication to placebo in people with stroke and
emotionalism (also known as emotional lability, pathological crying or laughing, emotional incontinence, involuntary emotional
expression disorder, and pseudobulbar affect).
Data collection and analysis
Two review authors independently selected studies, assessed risk of bias, extracted data from all included studies, and used GRADE to
assess the quality of the body of evidence. We calculated mean difference (MD) or standardised mean difference (SMD) for continuous
data and risk ratio (RR) for dichotomous data with 95% confidence intervals (CIs). We assessed heterogeneity using the I2 statistic.
The primary emotionalism measures were the proportion of participants achieving at least a 50% reduction in abnormal emotional
behaviour at the end of treatment, improved score on Center for Neurologic Study - Lability Scale (CNS-LS), Clinician Interview-
Based Impression of Change (CIBIC) or diminished tearfulness.
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Main results
We included seven trials with a total of 239 participants. Two trials were of cross-over design, and outcome data were not available
from the first phase (precross-over) in an appropriate format for inclusion as a parallel randomised controlled trial (RCT). Thus, the
results of the review are based on five trials with 213 participants. Treatment effects were observed on the following primary endpoints
of emotionalism: There is very low quality of evidence from one small RCT that antidepressants increased the number of people who
had 50% reduction in emotionalism (RR 16.50, 95% CI 1.07 to 253.40; 19 participants) and low quality evidence from one RCT
of improved scores on Center for Neurologic Study - Lability Scale (CNS-LS) and Clinician Interview-Based Impression of Change
(CIBIC) with antidepressants (RR 1.44, 95% CI 0.95 to 2.19; 28 participants). There was moderate quality evidence from three RCTS
that they increased the number of people who had a reduction in tearfulness (RR 2.18, 95% CI 1.29 to 3.71; 164 participants); and
low quality evidence from one RCT of improved scores on the Pathological Laughter and Crying Scale (PLCS) (MD 8.40, 95% CI
11.56 to 5.24; 28 participants).
Six trials reported adverse events (death) and found no difference between the groups in death (RR 0.59, 95% CI 0.08 to 4.50; 6 RCTs,
172 participants, moderate-quality evidence).
Authors’ conclusions
Antidepressantsmay reduce the frequency and severity of crying or laughing episodes based on very lowquality evidence.Our conclusions
must be qualified by several methodological deficiencies in the studies and interpreted with caution despite the effect being very large.
The effect does not seem specific to one drug or class of drugs. More reliable data are required before appropriate conclusions can
be made about the treatment of post-stroke emotionalism. Future trialists investigating the effect of antidepressants in people with
emotionalism after stroke should consider developing and using a standardised method to diagnose emotionalism, determine severity
and assess change over time; provide treatment for a sufficient duration and follow-up to better assess rates of relapse or maintenance
and include careful assessment and complete reporting of adverse events.
P L A I N L A N G U A G E S U M M A R Y
Pharmaceutical interventions for emotionalism after stroke
Review question
Does pharmaceutical treatment reduce the frequency of unwanted emotional displays in people with emotionalism after stroke compared
to placebo?
Background
Emotionalism often occurs after stroke. Emotionalism means that the person has difficulty controlling their emotional behaviour.
People after stroke may suddenly start crying or, less commonly, laughing for no apparent reason. This is distressing for that particular
person and their carers. Antidepressants, known to be helpful in people with depression, may be an effective treatment for emotionalism
after stroke, but there have been very few randomised controlled trials in this area.
Search date
We identified studies by searches conducted on 14 May 2018.
Study characteristics
We included seven randomised controlled trials involving 239 participants in the review, which reported on the use of antidepressants
for treating emotionalism. Trials ranged from small (10 participants) to large (92 participants). Mean/median age of participants ranged
from 57.8 years to 73 years. Studies were from Europe (UK: 1, Denmark: 1, Scotland: 1, and Sweden: 1); Asia (South Korea: 1; and
Japan: 1); and the USA: 1.
Key results
We included seven trials involving 239 participants (we identified no new trials since the previous version of the review). Two trials were
of cross-over design, and outcome data were not available from the first phase (precross-over) in an appropriate format for inclusion
as a parallel randomised controlled trial (RCT). Data were only available for five trials with 213 participants. We observed treatment
effects on the following: 50% reduction in emotionalism, improvements (reduction) in lability, Clinician Interview-Based Impression
2Pharmaceutical interventions for emotionalism after stroke (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
of Change (CIBIC), diminished tearfulness and scores on the Pathological Laughter and Crying Scale (PLCS). However, confidence
intervals were wide indicating that treatment may have had only a small positive effect, or even a small negative effect (in one trial). Six
trials reported death as an adverse event and found no differences between groups.
Quality of the evidence
We rated the evidence from very low to moderate quality due to these being small trials with some degree of bias.
Conclusion
Antidepressant drugs appear to reduce outbursts of crying or laughing. More trials with systematic assessment and reporting of adverse
events are needed to ensure that these benefits outweigh the risks.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Pharmaceutical interventions compared to placebo for emotionalism after stroke
Patient or population: emotionalism af ter stroke
Setting: inpat ient
Intervention: pharmaceut ical intervent ions
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with pharmaceuti-
cal interventions
Emotionalism: 50% re-
duct ion in emotional-
ism
0 per 1000 777 per 1000
(7 to 9)
RR 16.50
(1.07 to 253.40)
19
(1 RCT)
⊕©©©
Very lowa,b
Emotionalism: im-
proved score on Center
for Neurologic Study -
Lability Scale (CNS-LS)
643 per 1000 926 per 1000
(611 to 1000)
RR 1.44
(0.95 to 2.19)
28
(1 RCT)
⊕⊕©©
Lowa
Emotionalism: clinician
interview-based
impression of change -
improved score
643 per 1000 926 per 1000
(611 to 1000)
RR 1.44
(0.95 to 2.19)
28
(1 RCT)
⊕⊕©©
Lowa
Emotionalism: dim in-
ished tearfulness
292 per 1000 636 per 1000
(425 to 1000)
RR 2.18
(1.29 to 3.71)
164
(3 RCTs)
⊕⊕©©
Moderatec
Emotionalism: mean scores at end of treatment
- Pathological Laughter and Crying Scale (high
score = worse emotionalism)
MD 8.40 lower
(11.56 lower to 5.24
lower)
- 28
(1 RCT)
⊕⊕©©
Lowa
Lower score equals bet-
ter outcomes
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Adverse events: 1.
death: at end of treat-
ment
0 per 1000 0 per 1000
(2 to 92)
RR 0.59
(0.08 to 4.50)
172
(6 RCTs)
⊕⊕⊕©
Moderateb
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; MD: mean dif ference; OR: odds rat io; RCT : randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: we are moderately conf ident in the ef fect est imate; the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: our conf idence in the ef fect est imate is lim ited; the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: we have very lit t le conf idence in the ef fect est imate; the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aWe downgraded the quality of evidence as < 50 part icipants in total and only 1 study contributed to the analysis.
bWe downgraded the quality of evidence due to imprecision.
cWe downgraded the quality of evidence as we rated one of the studies at high risk for attrit ion bias.
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B A C K G R O U N D
Description of the condition
Disturbances of emotional behaviour, such as difficulty controlling
crying or laughing, are common after stroke (House 1989). Poeck
1969 distinguished two main types of disturbed emotionality as-
sociated with brain lesions: one he called pathological crying and
laughing, and the other emotional lability. The main differences
were that in the former, provocation was by non-emotive or incon-
gruous stimuli and the emotional display was socially abnormal
and unstable, while in the latter, emotional behaviour was more
socially familiar and provoked by typically emotive stimuli. The
terminology is used inconsistently in the literature (Allman 1989),
and the evidence to support Poeck’s dichotomy is not strong. In
order to avoid prejudging the issue we have preferred a general
term for all such disorders of emotionality and have called the
problem ’emotionalism’ - the habit of weakly yielding to emotion
(House 1989). The essential feature of emotionalism is an increase
in emotional behaviour - usually crying, but sometimes laughing
- that the patient reports as being outside normal control, so that
he or she cries or laughs in situations that would not previously
have provoked such behaviour. Onset of episodes is often reported
as being more sudden and unpredictable than usual but, even so,
themajority of sufferers report precipitants, which usually, but not
always, are congruent with their emotional response.
There are other disturbances of emotional behaviour after stroke,
especially irritable or anxious behaviours. By convention, however,
they are not included in the present category, which is restricted to
crying and laughing. Emotionalism is associated with an increase
in depressive symptoms. Nonetheless, most people with emotion-
alism do not have a diagnosable depressive disorder and many do
not have significant depressive symptoms at all (Calvert 1998; Kim
2000).
The reported prevalence of emotionalism varies across studies. Re-
sults of one systematic review, which included 15 English language
studies involving 3391 participants, indicated that emotionalism
affects about 17% of survivors in the first month, 20% between
one and six months, and 12% more than six months after stroke
(Gillespie 2016). It tends to decline in frequency and severity over
the first year, and a fewhave persistent severe problems. Peoplewith
emotionalism describe distress and embarrassment, and thereby
social avoidance and impaired quality of contact with friends and
family.
Description of the intervention
Until recently, there had been no Food and Drug Administration
(FDA)-approved drug to treat emotionalism. However, there are
several classes of drugs consistently used by clinicians in an off-
label manner. These drugs are mainly used to treat various cen-
tral nervous system conditions, targeting serotonin, monoamine,
or dopamine receptors. There are case reports and case series
suggesting that disorders of emotionality (variously named and
defined) may respond to mirtazepine (Kim 2005), imipramine
(Allman 1992a), amitriptyline (Schiffer 1983), doxepin (Schiffer
1983), nomifensine (Sandyk 1985), fluoxetine (Hanger 1993;
Nahas 1998; Panzer 1992; Sloan 1992), sertraline (Benedek 1995;
Mukand 1996; Muller 1999; Nahas 1998; Tan 1996), paroxetine
(Muller 1999), and also to lithium (Massey 1981), L-dopa (Udaka
1984; Wolf 1997), and venlafaxine (Smith 2003).
How the intervention might work
Classic tricyclic antidepressants commonly used to treat emo-
tionalism have actions as alpha-1-adrenoreceptor antagonists, his-
tamineH1 receptor antagonists, noradrenaline reuptake inhibitors
and 5HT reuptake inhibitors with varying affinities while the
mechanism of action of selective serotonin reuptake inhibitors
(SSRIs) is through blocking the reuptake of serotonin at neural
synapses by selectively inhibiting the 5HT transporter. For other
antidepressants such as mirtazepine, L-dopa works as a non-com-
petitive inhibitor of the N-methyl-D-aspartate glutamate recep-
tor. However, the effect of these drugs on the disorder of emo-
tionality remain unclear. It does not appear to be the result of a
simple antidepressant action, although amelioration of coexisting
depression, which is exacerbating the emotionalism, may be the
mechanism of action for some. Recovery occurs in people with-
out a depressive disorder; at times, it occurs in a dramatic fashion,
within 24 to48hours of starting a lowdose, and abnormal laughter
may also respond to treatment (Lauterbach 1991; Schiffer 1983).
There are case reports suggesting that withdrawal of antidepres-
sants leads to re-emergence of emotionalism, while reinstatement
leads to resolution (Schiffer 1983; Seliger 1989). However, drug
treatment is not always effective and may be complicated by com-
mon unacceptable side effects. We have been able to find two case
reports of psychological therapy (Brookshire 1970; Sacco 2008).
Why it is important to do this review
Emotionalism is an under-recognised and under-treated condition
that adversely affects individuals poststroke worldwide. Treatment
options include the off-label use of a range of antidepressants.
However, there are uncertainties surrounding the benefits over the
risks associated with their use. We undertook a systematic review
of all randomised controlled trials (RCTs) and quasi-RCTs (pub-
lished) of pharmaceutical agents for the treatment of emotional-
ism associated with stroke. We did not find any RCTs evaluating
non-drug (psychological) interventions; we will consider any fu-
ture trials in this area in a separate review.
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O B J E C T I V E S
The primary objective was to determine whether pharmaceutical
treatment reduces the frequency of emotionalism or emotional
displays after stroke.
The secondary objectives were to determine whether treatment
improves social functioning or health-related quality of life after
stroke or their principal caregivers. We also aimed to determine
the safety, adherence to, and acceptance of treatment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered all relevant randomised controlled trials (RCTs) in
people with a clinical diagnosis of stroke, where a pharmaceuti-
cal agent used specifically for the treatment of emotionalism was
compared with placebo.We excluded trials in which the allocation
to treatment or placebo was not random. We excluded trials that
compared two or more antidepressant drugs, but which did not
include a placebo group. We identified RCTs and cross-over trials
in all languages. There was no restriction on eligibility of RCTs
on the basis of sample size, duration of follow-up, or publication
status.
When we found studies meeting all the criteria for inclusion, but
not presenting any outcome data (and such data were not available
from the authors) and could therefore not contribute to any pooled
estimate of effect, we regarded these studies as ’dropouts’ rather
than ineligible, and they are listed in Table 1 to indicate that they
have not been overlooked.
Types of participants
All participants had to have established emotionalism at entry into
the trial. The essential feature of emotionalism is an increase in
emotional behaviour - usually crying, but sometimes laughing -
that the patient reports as being outside normal control, so that
he or she cries or laughs in situations that would not previously
have provoked such behaviour. Onset of episodes is often reported
as being more sudden and unpredictable than usual, but even so
most people report precipitants, which usually are congruent with
their emotional response.
We included all participants with a confirmed history of stroke,
at any stage after onset, where there was an explicit intention to
provide a pharmacological agent to treat emotionalism associated
with stroke. Stroke was defined according to standard clinical crite-
ria. The criteria include cerebral infarction, intracerebral haemor-
rhage and uncertain pathological subtypes, but exclude subarach-
noid haemorrhage, which has a different natural history and man-
agement strategy to other stroke subtypes. There were no restric-
tions on the basis of age, sex, or other characteristics. We excluded
trials that included mixed populations (such as stroke and head
injury or other central nervous system disorders) unless separate
results for those with stroke could be identified. We included peo-
ple with a diagnosed mood disorder or a mood score above the
standard cut-off scores at baseline, provided it was clear that they
also met criteria for emotionalism. We excluded those who were
being treated primarily for a stroke-associated pain syndrome or
for stroke-associated depression, even if emotionalism was mea-
sured as a secondary (post hoc) outcome.
Types of interventions
We included any trial that attempted to evaluate a compari-
son between a pharmacological agent and placebo for the treat-
ment of emotionalism following stroke. Specific pharmacolog-
ical agents considered included tricyclic antidepressants (e.g.
nortriptyline, imipramine, and clomipramine), selective sero-
tonin reuptake inhibitors (SSRIs) (e.g. fluvoxamine, fluoxetine,
citalopram, sertraline, citraline and paroxetine), monoamine ox-
idase inhibitors (MAOIs) (e.g. moclobemide), and other antide-
pressant medications. We found no trials of psychostimulants
(e.g. methylphenidate), mood stabilisers (e.g. lithium), benzodi-
azepines, or combined preparations. We will include any future
trials but will analyse them separately.
Types of outcome measures
Primary outcomes
Emotionalism: despite widespread acknowledgement of the im-
portance of the problem, there is no widely accepted standardised
set of diagnostic criteria for emotionalism. Therefore, we planned
the primary emotionalism endpoint to be the proportion of par-
ticipants who, at the end of treatment, met the criteria for emo-
tionalism that were applied by the study authors in recruiting to
the trial. However, data for this endpoint were not available. In
the current review, the primary emotionalism measures were as
follows.
• The proportion of participants achieving at least a 50%
reduction in abnormal emotional behaviour at the end of
treatment.
• Improved score on Center for Neurologic Study - Lability
Scale (CNS-LS).
• Clinician Interview-Based Impression of Change (CIBIC).
• Diminished tearfulness.
Secondary outcomes
• Emotionalism: mean scores at end of treatment. There are a
number of measures reported in the published literature (Allman
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1992b; Moore 1997; Newsom-Davis 1999; Robinson 1993a),
but apart from frequency of emotional behaviour, there is no
widely accepted standardised measure of severity of emotionalism
that could be used to measure outcome as a continuous variable.
• Depression: mean scores at end of treatment.
• Depression: average change in scores between baseline and
end of treatment. Depression, as measured on scales, such as the
Hamilton Depression Rating Scale (HDRS) (Hamilton 1960),
Montgomery Åsberg Depression Rating Scale (MADRS)
(Montgomery 1979), Geriatric Depression Scale (GDS)
(Gompertz 1993), Beck Depression Inventory (BDI) (Beck
1961), and Hospital Anxiety and Depression Scale (Depression
subscale, HADS-D) (Zigmond 1983), or as measured on
composite scales, such as the General Health Questionnaire
(GHQ) (Goldberg 1972).
• Cognitive functioning: mean scores at end of treatment.
Cognition as measured on scales such as the Mini-Mental State
Examination (MMSE) (Folstein 1975).
• Activities of daily living: mean scores at end of treatment.
Activities of daily living as measured on scales such as the Barthel
Index (BI) (Mahoney 1965).
• Disadvantages of treatment were recorded as:
◦ adverse events: death
◦ adverse events: all
◦ adverse events: leaving the study early (including
death).
• We identified additional endpoints for use in further
reviews, where measured.
◦ Proportion who no longer meet the trial authors’
criteria for emotionalism.
◦ Proportion who scored above accepted cut-offs for
identifying mood disorders, using mood rating scales.
◦ Proportion who met the standard psychiatric
diagnostic criteria for major depression or dysthymia (Diagnostic
and Statistical Manual of Mental Disorders (DSM): DSM-IIIR,
DSM-IV) (APA 1987; APA 1994).
◦ Mean change in handicap from baseline to follow-up,
as measured on scales, such as the Modified Rankin Scale (mRS)
(van Swieten 1998).
◦ Mean change in health-related quality of life from
baseline to follow-up, as measured on scales such as the 36-item
Short Form questionnaire (SF-36) (Ware 1993), or the
Nottingham Health Profile (NHP) (Hunt 1986).
Search methods for identification of studies
This review is an update of a previously published Cochrane Re-
view (Hackett 2010). The first published review was in 2004
(House 2004; Appendix 1). For this update, we searched all
databases from 2008 until May 2018.
Specialised Register of Cochrane Stroke
Cochrane Stroke’s Information Specialist searched the Specialised
Register of Cochrane Stroke on 14 May 2018.
Electronic searches
We searched the following databases on 14 May 2018.
• Cochrane Central Register of Controlled trials
(CENTRAL): Issue 4, 2018, the Cochrane Library (Appendix 2).
• MEDLINE (OVID): 1966 to May 2018 (Appendix 3).
• Embase (OVID): 1980 to May 2018 (Appendix 4).
• CINAHL (EBSCO): 1982 to May 2018 (Appendix 5).
• PsycINFO (OVID): 1967 to May 2018 (Appendix 6).
• BIOSIS Previews (Web of Science): January 2002 to May
2018 (Appendix 7).
• Web of Science (ISI): January 2002 to May 2018
(Appendix 8).
Searching other resources
We also searched the following resources using (“emotion” or
“laughing” or “tearful” or “pseudobulbar affect” and “stroke” or
“cerebral hemorrhage” or “brain ischemia” from inception to May
2018.
• ClinicalTrials.gov (clinicaltrials.gov).
• World Health Organization International Clinical Trials
Registry Platform ( WHO ICTRP) ( who.int/ictrp/en/).
• ProQuest Dissertations and Theses Database.
We also searched abstracts and conference proceedings from the
following international conferences for relevant studies.
• European Stroke Conference (2011 to 2018).
• Stroke Society of Australasia Annual Scientific Meetings
(2011 to 2017).
• World Stroke Congress (2000 to 2016).
• Asia Pacific Stroke Conference (2011 to 2017).
The full search strategies for other resources are in Appendix 9.
Personal communication
We contacted the study authors for information on ongoing stud-
ies or to request additional study data.
Reference lists
We searched the reference lists of relevant trials, systematic reviews
and reviewed chapters in books on the prevention and treatment of
depression and management of stroke, including but not limited
to, reviews of themanagement of stroke, books specifically directed
at the treatment or prevention of depression, and those on stroke
and old age.
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Data collection and analysis
Selection of studies
Two review authors (SA, MH) discarded irrelevant citations based
on the title of the publication and its abstract. In the presence of
any suggestion that an article could possibly be relevant, we re-
trieved the full-length article for further assessment. Two review
authors (SA, MH) independently selected the trials for inclusion
in the review from the culled citation list. We obtained transla-
tions of potentially relevant non-English articles. We resolved dis-
agreements by discussion, and one review author (AH) confirmed
the final list and adjudicated any persisting differences. The se-
lection process is presented in a PRISMA flow diagram (Liberati
2009). We listed the included studies under Characteristics of
included studies, and studies that we ultimately excluded under
Characteristics of excluded studies and provided the primary rea-
sons for exclusion.
Data extraction and management
Two review authors (SA, MH) extracted study characteristics and
outcome data from included studies, independently, on specially
designed forms. We cross-checked and entered the data into Re-
view Manager 5 (Review Manager 2014). We obtained missing
information from the study authors when possible. We resolved
disagreements by discussion or through consultation with a third
review author (AH). If outcome data were not reported in a us-
able way, we reported this in the notes in the Characteristics of
included studies table.
We collected data on:
• the report: author, year and source of publication;
• the study: sample characteristics, social demography,
definition and criteria used for emotionalism;
• the participants: stroke sequence (first-ever versus
recurrent), social situation, time since stroke onset, history of
psychiatric illness, current neurological status, current treatment
for depression, coronary artery disease;
• the research design and features: sampling mechanism,
treatment assignment mechanism, adherence rates, non-response
rates, length of follow-up;
• the intervention: type, duration, dose, timing, mode of
delivery;
• the effect size: sample size, nature of outcome, estimate and
standard error.
To allow an intention-to-treat analysis, we sought data irrespective
of adherence, whether or not the participants were subsequently
deemed ineligible, or otherwise excluded from treatment or follow-
up.
We checked all of the extracted data for agreement between review
authors. We obtained missing information from the study investi-
gators whenever possible. To avoid introducing bias, we requested
this unpublished information in writing, and then entered it into
Review Manager 5 (Review Manager 2014).
Assessment of risk of bias in included studies
Two review authors (SA, MH) independently assessed risk of bias
for each study using the criteria outlined in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). We
resolved any disagreements by discussion or by involving another
author (AH). We assessed the risk of bias according to the follow-
ing domains.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective outcome reporting.
• Other bias.
In accordance with the Cochrane ’Risk of bias’ assessment tool,
we graded potential sources of bias as high, low, or unclear and
provided a quote from the study report together with justification
for our judgement in the ’Risk of bias in included studies’ table.
We summarised the risk of bias judgements across different studies
for each of the domains listed.
When considering treatment effects, we have taken into account
the risk of bias for the studies that contributed to that outcome.
Measures of treatment effect
Dichotomous data
The primary outcomes of interest were the proportion of partici-
pants who met the diagnostic categories for emotionalism at the
end of follow-up (with improved score on Center for Neurologic
Study - Lability Scale (CNS-LS), Clinician Interview-Based Im-
pression of Change (CIBIC), and diminished tearfulness), and the
proportion that show a 50% reduction in abnormal emotional
behaviour (crying or laughing) at the end of treatment. For all di-
chotomous outcomes, we calculated Mantel-Haenszel risk ratios
(RRs) with 95% confidence intervals (CIs) where appropriate, us-
ing random-effects analyses.
Continuous data
For continuous outcomes, if ordinal scale data appeared to be ap-
proximately normally distributed or if the analysis suggests para-
metric tests were appropriate, we treated the outcome measures as
continuous. If there were at least two studies that reported the same
outcomes, then we calculated a mean difference (MD) across the
trials. Where different outcome measures were used, we planned
to calculate a standardised mean difference (SMD).
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Unit of analysis issues
No unit of analysis issues were anticipated in the studies we in-
cluded.
Dealing with missing data
Wewrote to the authors of all included studies requesting data that
were unavailable or ambiguous in the published articles. Three
authors responded with the requested additional data (Andersen
1993; Murray 2005; Robinson 1993b). Another study author re-
sponded, stating that the requested additional data were unavail-
able (Burns 1999). We did not receive responses from the remain-
ing study authors.
Assessment of heterogeneity
We assessed clinical and methodological heterogeneity by exam-
ining the study characteristics of studies. We used the I2 statistic
to measure heterogeneity among the trials in each analysis (Deeks
2011). We reported similarities between interventions, partici-
pants, design, and outcomes in the Included studies subsection.
Assessment of reporting biases
We created funnel plots, however, due to the small number of in-
cluded studies, these are unlikely to be useful in exploring possible
small study biases for the primary outcome.
Data synthesis
We analysed data using Review Manager 5 software and pooled
data for meta-analysis when studies assessed similar treatment and
had similar outcomes (Review Manager 2014). We conducted a
meta-analysis using available or calculated SMDs for continuous
outcomes, and risk ratios (RRs) for dichotomous outcomes. We
included in the results measures of uncertainty, such as 95% CIs
and estimates of I2.
Summary of findings and quality of the evidence
We also assessed the quality of evidence according to GRADE
(Atkins 2004), by constructing a ’Summary of findings’ table for
the main outcomes using the GRADEPro tool (GRADEproGDT
2015; Schunemann 2011). We reported the primary outcomes in
’Summary of findings for the main comparison’.
Subgroup analysis and investigation of heterogeneity
If there were at least two trials that reported the same outcomes,
we reviewed the data for appropriateness of pooling. If there was
definite evidence of heterogeneity (I2 > 50%), we explored the po-
tential reasons for the differences by performing subgroup analy-
ses. If the heterogeneity could not be explained, we combined the
trials using random-effects analyses with cautious interpretation,
or did not combine them at all. Where possible, we performed
subgroup analyses to examine the impact of treatment type and
duration, and of stroke severity.
Sensitivity analysis
We planned to undertake sensitivity analyses to explore the influ-
ence of date of publication, sample size, duration of follow-up,
treatment type, high (over 20%) number of dropouts, and blinded
versus unblinded outcome assessors. We explored the sensitivity
of the combined estimate to individual trials by leaving one study
out due to high risk of bias and methodological differences. We
then calculated the combined effect of the remaining trials, and
compared the results with the combined effect based on all the
trials.
R E S U L T S
Description of studies
Results of the search
In total, we identified 2802 records, of these, we retrieved 2244
records through database searching. We found 558 additional ref-
erences by searching other resources. After removing 559 dupli-
cates, we screened 2243 titles and abstracts and excluded 2232
irrelevant records. We retrieved full-text reports for the remaining
11 studies. After reading the full-texts, we excluded 10 studies as
they did not meet the review eligibility criteria. We have provided
primary reasons for exclusion in the Characteristics of excluded
studies table and in Figure 1. Although, one trial met the inclusion
criteria, baseline evaluation of the study occurred at one month
post-treatment (Kim 2017a); we considered this study a ’dropout’
(Table 1).
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Figure 1. Study flow diagram.
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In the previous published versionof this review (Hackett 2010), we
identified two trials that met the inclusion criteria (Aizawa 1977;
Ohtomo 1985). However, both trials included participants with
cerebral arteriosclerosis and neither presented outcome data by
those diagnosed with emotionalism at entry. We considered these
two studies as ’dropouts’. SeeTable 1 formore detailed information
on these trials.
Included studies
From the previous update of this review, there were a total of seven
included studies with 239 participants (of whom we included 213
participants in themeta-analysis). Two trials were of cross-over de-
sign (Andersen 1993; Ohkawa 1989), and outcome data were not
available from the first phase (precross-over) in an appropriate for-
mat for inclusion as a parallel randomised controlled trial (RCT).
Therefore, this review primarily reports data from five trials with
213 participants (see Characteristics of included studies). Of these,
we had included five studies in the first version of this review in
2004 (Andersen 1993; Brown 1998; Burns 1999; Ohkawa 1989;
Robinson 1993b), and we added two studies to the previous up-
date in 2010 (Choi-Kwon 2006; Murray 2005). For this present
review, we found no new studies.
Participants
All trials in this review included men and women. The mean or
median age of participants ranged from 57.8 to 73 years. Five trials
reported the time between stroke and randomisation into the trial,
with the range covering three days to 13 years (Andersen 1993;
Burns 1999; Murray 2005; Ohkawa 1989; Robinson 1993b).
Interventions
Five trials assessed the efficacy of SSRIs: citalopram (Andersen
1993), fluoxetine (Brown 1998; Choi-Kwon 2006), and sertra-
line (Burns 1999;Murray 2005); two assessed tricyclic antidepres-
sants: amitriptyline (Ohkawa 1989), and nortriptyline (Robinson
1993b). Duration of treatment ranged from 10 to 182 days.
Comparator intervention(s)
Only one study did not compare the active intervention with a
placebo-matched control, but combined the active treatment with
a ’stomach medicine’ to disguise taste and smell with the control
group receiving the stomach medicine only (Ohkawa 1989).
Outcomes
Primary outcome: emotionalism
No standard criteria were used to define emotionalism at entry
across the trials. Emotionalism was measured in seven different
ways in the seven trials (Andersen 1993; Brown 1998; Burns
1999; Choi-Kwon 2006; Murray 2005; Ohkawa 1989; Robinson
1993b), and no more than two trials used the same method of
assessment. Andersen 1993 assessed emotionalism using a semi-
structured interview modified from Lawson and Macleod. Brown
1998 used the Lawson-Mcleod Rating Scale. In Burns 1999, the
presence or absence of emotionalismwas assessed using sevenques-
tions based on the study by House et al (House 1989). Other
studies confirmed the presence of emotionalism through clinical
diagnosis made by a psychiatrist (Robinson 1993b), or asking the
patients and their relatives whether or not increased tearfulness
or inappropriate laughing has occurred at anytime (Choi-Kwon
2006), or on more than two occasions (Murray 2005).
Secondary outcomes
A variety of additional outcomes were assessed in each trial. Sev-
eral trials assessed, but did not report, outcome data for depres-
sion (Andersen 1993; Brown 1998; Burns 1999; Ohkawa 1989),
activities of daily living (Burns 1999), and cognitive functioning
(Burns 1999; Ohkawa 1989). Only three studies reported having
systematically measured and reported adverse events (Burns 1999;
Choi-Kwon 2006; Murray 2005).
Excluded studies
We have listed the 23 excluded studies and the reasons for their
exclusion in the Characteristics of excluded studies table. The
main reasons for exclusion were no placebo used (Atarashi 1988;
Bassi 1984;Muller 1999), participants had not experienced stroke,
or the number with stroke was unclear (Aizawa 1977; Bassi
1984; Doody 2014; Lawson 1969; Ohtomo 1985; Otomo 1984;
Sauve 2017; Udaka 1984), not a RCT (Allen 2018; Chen 2010;
Colamonico 2012; Manzo 1998; Work 2011), open-label trials
(D’Amico 2017; Formella 2017a; Formella 2017b; Seliger 1992),
emotionalism was not investigated either at baseline (Rasmussen
2000), or at end of treatment (Moller 2007), and baseline evalua-
tion of emotionalism occurred at one month post-treatment (Kim
2017a).
Ongoing studies
We identified no ongoing studies.
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Studies awaiting classification
We identified no studies awaiting classification.
New studies found at this update
We identified no new studies in this update.
Risk of bias in included studies
We present Figure 2, a graphical summary of ’Risk of bias’ as-
sessments we performed for the seven included studies, based on
the seven risk of bias domains. Figure 3 provides a summary of
risk of bias for each included study. We have provided the reasons
for judgements in the Risk of bias in included studies tables. For
clarification, we have provided quotes in these tables.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We rated three studies as having a low risk of selection bias and
four as having an unclear risk. Two of the studies did not report
the method used for sequence generation (Brown 1998; Ohkawa
1989). Four studies randomised participants using a randomnum-
ber allocation list (Burns 1999), or computer-generated num-
ber sequence (Andersen 1993; Choi-Kwon 2006; Murray 2005).
One study administered the intervention after random number as-
signment (Robinson 1993b). Allocation concealment was clearly
reported in four studies (Andersen 1993; Brown 1998; Murray
2005; Robinson 1993b).
Blinding
We assessed blinding as having a low risk of performance and
detection bias in four studies (Brown 1998; Choi-Kwon 2006;
Ohkawa 1989; Robinson 1993b). Although three studies reported
that they were double-blind, they failed to report exactly who was
blinded (Andersen 1993; Burns 1999; Murray 2005).
Incomplete outcome data
We judged six of the studies as having a low risk of bias for outcome
reporting (Andersen 1993; Brown 1998; Burns 1999; Murray
2005; Ohkawa 1989; Robinson 1993b). One study was at high
risk, as the total number of participants stated is inconsistent. We
rated studies as having a high risk of bias if dropout rates were
uneven between groups and the reason for dropout was suspected
to be related to group allocation. We also rated studies as high risk
if investigators did not report how dropout was dealt with (e.g.
intention-to-treat analysis and last observation carried forward).
Selective reporting
We rated risk of bias from selective reporting as low risk for all the
studies (Andersen 1993; Brown 1998; Burns 1999; Choi-Kwon
2006; Murray 2005; Ohkawa 1989; Robinson 1993b).
Other potential sources of bias
We judged other risk of bias as unclear risk for all the studies as we
did not detect other potential sources of bias; they reported their
funding source.
Effects of interventions
See: Summary of findings for the main comparison
Pharmaceutical interventions compared to placebo for
emotionalism after stroke
There are seven trials with 239 participants. Two trials were of
cross-over design and outcome data were not available from the
first phase (precross-over) in an appropriate format for inclusion
as a parallel randomised controlled trial (RCT). Thus, the results
of the review were based on five trials with 213 participants. For
details of the comparisons made for trials with outcome data, refer
to the Data and analyses section. Labelling of the x-axis on the
forest plots changes due to variation in themethodofmeasurement
and direction of the outcome scale.
Primary outcome
Emotionalism
We observed treatment effects on the primary endpoint of emo-
tionalism: 50% reduction in emotionalism (risk ratio (RR) 16.50,
95% confidence interval (CI) 1.07 to 253.40; 1 RCT, 19 partici-
pants, very low-quality evidence; Brown 1998; Analysis 1.1, sub-
group 1.1.1); improvements (reduction) in tearfulness (RR 2.18,
95% CI 1.29 to 3.71; 3 RCTs, 164 participants, moderate-quality
evidence; Burns 1999; Choi-Kwon 2006; Murray 2005; Analysis
1.1, subgroup 1.1.4); improved score on Center for Neurologic
Study - Lability Scale (CNS-LS) and Clinician Interview-Based
Impression of Change (CIBIC) (RR 1.44, 95% CI 0.95 to 2.19; 1
RCT, 28 participants, low-quality evidence; Burns 1999; Analysis
1.1); and lower (better) scores on the Pathological Laughter and
Crying Scale (PLCS) (mean difference (MD) 8.40, 95% CI 11.56
to 5.24; 1 RCT, 28 participants, low-quality evidence; Robinson
1993b; Analysis 1.2, subgroup 1.2.1). The point estimates were
consistent with large treatment effects for all five trials; however,
the CIs were wide for three trials (Brown 1998; Burns 1999;
Robinson 1993b), so it is possible that the treatmentmay have had
only a small positive effect, or in the case of the one trial (Burns
1999), may even have had a small negative effect on two endpoints
(see subgroups 1.1.2 and 1.1.4).
Secondary outcomes
Depression
The moderate reduction in depression that was observed between
treatment groups at the end of one study (Robinson 1993b;
Analysis 1.3, subgroup 1.3.1), has been mediated by the addition
of a second study (Murray 2005), and is not apparent after con-
trolling for differences in depression between groups at baseline
(standardised mean difference (SMD) 0.82, 95% CI 2.14 to 0.51;
2 RCTs, 72 participants) (see Analysis 1.4, subgroup 1.4.1, where
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the CI includes unity and the possibility of a negative treatment
effect).
Cognitive functioning
One study provided data concerning this outcome, revealing that
pharmaceutical interventions had no effect on cognitive function-
ing (MD 0.30, 95% CI -3.27 to 2.67; 1 RCT, 28 participants;
Robinson 1993b; Analysis 1.5) compared with placebo.
Activities of daily living
One study addressed activities of daily living and found no treat-
ment effect on activities of daily living (MD 1.40, 95% CI -5.22
to 2.42; 1 RCT, 28 participants; Robinson 1993b; Analysis 1.6).
Disadvantages of treatment
Two studies systematically recorded and reported adverse events
(Burns 1999; Murray 2005). Other studies provided selected data
on some adverse events (Robinson 1993b), or those leaving the
study early (Brown 1998; Choi-Kwon 2006).
Death
We saw no differences between groups with the six studies report-
ing deaths (RR 0.59, 95% CI 0.08 to 4.50; 6 RCTs, 172 partic-
ipants, moderate-quality evidence; Andersen 1993; Brown 1998;
Burns 1999; Murray 2005; Ohkawa 1989; Robinson 1993b;
Analysis 1.7). Deaths occurred in two studies, one in each group
(Burns 1999), and one death only in the placebo group (Murray
2005).
All adverse events
We saw no difference between groups. Confidence intervals were
extremely wide and all included unity (see Analysis 1.8).
Leaving the study early
Two studies showed that participants allocated active treatment
were less likely to leave the studies early (Choi-Kwon 2006;Murray
2005), three other studies showed participants allocated active
treatment were more likely to leave the studies early, giving a
pooled estimate of no effect. However, CIs were extremely wide
(Brown 1998; Burns 1999; Choi-Kwon 2006; Robinson 1993b),
and all included unity (see Analysis 1.9).
D I S C U S S I O N
Summary of main results
The results of this review indicate that antidepressants reduce the
frequency and severity of crying episodes. While these findings
appear straightforward, our conclusions are guarded because of
several methodological deficiencies in the studies; we have down-
graded the quality of the evidence accordingly (see Summary of
findings for the main comparison). These deficiencies include the
type of participants included, the definition and diagnosis of emo-
tionalism used, the inclusion of some comorbidities, the small
number of trials and participants contributing to most endpoints,
and the generally poor trial design and reporting of results.
In general, clinical trials are carried out on selected groups of in-
dividuals, while the usefulness of the information derived lies pri-
marily in the ability to generalise the data to a wide range of indi-
viduals. This review included trials with participants whose index
stroke varied from six days to 13 years before randomisation. It
may not be appropriate to consider that the response to treatment
is consistent across such mixed populations as the aetiology (and
underlying pathology) of emotionalism may differ between pa-
tients early after acute stroke and those who survive in the long
term. For example, survivors in the acute phase have recently ex-
perienced a potentially life-threatening event and are coping with
the psychological consequences, as well as recovering from the dis-
abling effects of the stroke itself. On the other hand, survivors
of stroke at several months or longer after the event are adjust-
ing to the prospects of long-term disability and changes in social
and financial circumstances, as well as the cumulative effects of
cerebrovascular disease or vascular dementia, or both. The natural
history of emotionalism after stroke is for spontaneous resolution
over a few months, whereas it is reasonable to suppose that it may
be a more chronic state in those with chronic cerebrovascular dis-
ease. Therefore, since the balance of risks and benefits and the
effectiveness of treatment for emotionalism may change with time
from the onset of stroke, mixing individuals at very different stages
after stroke makes interpretation difficult. Future trials should in-
clude homogeneous patient groups with respect to time from the
onset of stroke, or sufficient numbers of participants in the early
and late stages after stroke.
Defining the disorder of interest is key to the conduct of a clini-
cal trial. A widely agreed definition usually exists for most clinical
conditions. However, no such standard definition is available for
emotionalism. For example, it does not feature in a clearly defined
way in the Diagnostic and Statistical Manual of Mental Disor-
ders (DSM) (APA 1987; APA 1994; APA 2017), or International
Classification of Diseases (ICD) (ICD 10). In the clinical setting
the diagnosis is generally made during interview. The commonly
accepted criteria for emotionalism include: 1) sudden onset of
crying (and less commonly, laughing); 2) not under usual control
(a change in behaviour has occurred); and 3) the crying is not
simply an expression of depression or grief. Given the resource-
intensive nature of conducting psychiatric interviews on all partic-
ipants in clinical trials, we considered it acceptable to determine
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caseness during a psychiatric interview and to measure frequency
and severity using a validated questionnaire. We used two stan-
dardised scales to assess emotionalism: the Pathological Laughter
and Crying Scale (PLCS) (Robinson 1993b), and the Lawson and
Macleod Scale (Lawson 1969). An attempt to validate the PLCS
was made (Robinson 1993b), but neither scale has been externally
validated using traditional methods. The ’severity’ score on the
PLCS includes items recording the quality of crying, not just fre-
quency of occurrence. In the absence of a validated questionnaire,
the most appropriate method to diagnose and determine severity
of emotionalism is likely to be a simple and easily replicable assess-
ment of the frequency of crying episodes, or laughing episodes (as-
sessing these elements separately), combined with an a priori cut-
off score for entry into the trial. The nature of precipitants should
be assessed in separate questions to those assessing frequency of
crying and laughing.
Emotionalism is known to be confounded by depression (House
1989). Tearfulness canbe the result of anunderlyingdepressive dis-
order. The inclusion of participants with depression and emotion-
alism limits our ability to draw conclusions regarding the treatment
of emotionalism alone. While all included studies assessed depres-
sion, only two studies reported results (Murray 2005; Robinson
1993b). Ideally, future studies should limit inclusion to partici-
pants with emotionalism alone, or recruit sufficient participants
to allow adjustment for depression in the results, and report the
results from all questionnaires administered.
As is often noted in reviews of the literature, there were several
deficiencies in trial methods that further limit our findings. First,
most trials (with the exception of Ohtomo 1985) were small, with
only three trials reporting adequate concealment of the randomi-
sation sequence (Brown 1998; Choi-Kwon 2006; Murray 2005).
The duration of treatment was short for most studies. Observa-
tional studies suggest that many cases of emotionalism resolve over
the first months after stroke, so the impact of short-term therapy
may be difficult to assess. Furthermore, case histories report re-
lapse in emotionalism upon withdrawal of treatment, so it would
be useful to have information on longer-term results and relapse
rates in future studies. We also included cross-over studies if the
washout period was deemed appropriate. While the benefits and
risks of treatment with antidepressants appear to be balanced, only
one trial systematically recorded and reported all adverse events
in the study, making an accurate presentation of the benefits and
risks impossible (Burns 1999).
In summary, these trials appear to add little to case reports and
case series. They provide suggestive, but not definitive, evidence
that antidepressants can reduce the frequency of crying (sometimes
abolishing it altogether). The effect does not seem specific to one
drug or class of drugs.
Overall completeness and applicability of
evidence
The present review included seven trials with a total of 239 par-
ticipants (Andersen 1993; Brown 1998; Burns 1999; Choi-Kwon
2006; Murray 2005; Ohkawa 1989; Robinson 1993b). Two tri-
als were of cross-over design (Andersen 1993; Ohkawa 1989),
and outcome data were not available from the first phase (pre-
cross-over) in an appropriate format for inclusion as a parallel ran-
domised controlled trial (RCT). Thus, the results of the review
were based on five trials with 213 participants. Overall, there were
no standard criteria for defining emotionalism at entry and no
standard measures of emotionalism across all the included studies.
We considered three studies as ’dropouts’ as outcome data were
not available in the format appropriate for a parallel RCT and
baseline was completed post-treatment. As a result, there were a
small number of studies and participants contributing to most
endpoints. The accuracy of the findings of this systematic review
and meta-analysis is based on the studies which met the eligibility
criteria. We will incorporate new data in future updates.
Quality of the evidence
We rated the quality of evidence for all comparisons using the
five GRADE considerations (study limitations, consistency of ef-
fect, indirectness, imprecision and publication bias; Schunemann
2011). We created a ’Summary of findings’ table. Quality assess-
ment ranged from very low to moderate.
Limitations in study design or execution
Concerning the comparison of pharmaceutical interventions with
placebo for diminished tearfulness, we downgraded the quality
of evidence by one point for strong suspicions of attrition bias,
related to the inconsistency in the total number of participants
included in the analysis.
Inconsistency of results
We downgraded the quality of evidence by two points for the
following outcomes: 50% reduction in emotionalism, improved
score on Center for Neurologic Study - Lability Scale (CNS-LS),
Clinician Interview-Based Impression of Change (CIBIC), and
PLCS scores, as there were fewer than 50 participants and only
one trial contributing to the analysis on each of these outcomes.
Indirectness of evidence
All included studies addressed the main review question (PICO):
the effect of pharmaceutical interventions compared to placebo in
reducing the frequency of emotionalism and emotional displays
poststroke. Thus, we did not downgrade any outcomes in any
comparisons for indirectness of evidence.
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Imprecision
We downgraded the quality of evidence for 50% reduction in
emotionalism and death by one point owing to wide confidence
intervals.
Publication bias
We did not downgrade the quality of evidence for publication bias
in any of the outcomes, as we did not detect publication bias.
Potential biases in the review process
Strengths and weaknesses of this review
This review has rigorously adhered to the Cochrane methods for
performing systematic reviews.During the review process, we have
tried to avoid and minimise any biases. We undertook extensive
searches of databases and additional resources. We did not apply
any language restrictions within the search process. Thus, we be-
lieve that we have identified and included all potentially relevant
studies in this review. We arranged for any relevant and non-rel-
evant non-English full-text studies to be translated into English,
to finalise the eligibility process. Furthermore, at least two review
authors independently extracted and managed the data.
The main weakness of this review is the inadequate reporting of
some of the studies, which has precluded classification of risk of
bias as either low or high risk. This has led us to rate some of
the studies across the categories at unclear risk of bias, with a
small number of studies and participants contributing to most
endpoints.
Agreements and disagreements with other
studies or reviews
To date, there are no similar meta-analyses investigating the use
of pharmacological interventions in reducing the frequency of
emotional displays in people with emotionalism after stroke, with
which to compare our findings.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Antidepressants may reduce the frequency of emotionalism after
stroke. However, there is continued uncertainty about who might
benefit the most from treatment among those who meet the clini-
cal features indicative of emotionalism. There are no data to guide
recommendations about how longpatients should remain on treat-
ment, or what side effects may be expected. Given the limited ev-
idence, clinicians and patients may consider a therapeutic trial of
antidepressants when emotionalism is persistent and severe.
Implications for research
We recommend that future trials investigating the effect of antide-
pressants in people with emotionalism after stroke should:
• use a standardised method to diagnose emotionalism,
determine severity and assess change over time: this would
assume development of a standard definition of emotionalism;
• use a standard measure of depression as the major
confounder to be considered in analyses;
• recruit an adequate number of participants so that variables
such as ’concomitant depression’ and ’time passed between stroke
and recruitment’ can be controlled;
• provide treatment for a sufficient duration and follow-up, so
that rates of relapse or maintenance of remission can be assessed;
• include careful assessment and complete reporting of
adverse events;
• limit the number of outcomes to three or four and report
results for all outcomes;
• make the outcomes relevant to the individual participant
by, for example, being clear whether reduction in crying
frequency or change in crying behaviour represented a
satisfactory outcome for the participant;
• ensure the theoretical or biological rationale, or both, and
sequential development of interventions follow a recommended
framework for development, and if a framework is followed then
it must be reported in the main study publications (Walker
2017);
• complete intervention descriptions to increase research
usability, replicability, and development of standardised
interventions, as an identified priority for the world stroke
agenda (Walker 2017);
• adopt an implementation fidelity model or framework at
the design stage (Walker 2017).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Andersen 1993
Methods Study design: randomised, cross-over design
Number of arms: 2
Experimental arm: citalopram 20 mg/day if under 66 years old, 10 mg/day if older
Control arm: placebo
Analysis: per protocol: 1 withdrawn (placebo), excluded from analysis; 2 early dropouts
(placebo), last value carried forward
Participants Geographical location: Denmark
Setting: Aalborg Hospital
Number of participants: 16
Diagnosis: stroke, 6 to 913 days prior to randomisation
Inclusion criteria: not specified
Exclusion criteria: 1) aphasia, (2) if participants or spouse is unable to keep a diary
Age: median age 58.5 years, range 40 to 83 years. Mean not reported
Sex: 88% men
Emotionalism criteria: involuntary outbursts of crying
Interventions Treatment: citalopram20mgdaily if under 66 years old, 10mgdaily for older participants
Control: matched placebo
Cross-over details: 7 days baseline; 21-day intervention; 7-day washout. 7-day baseline;
21-day intervention
Duration: treatment continued for 21 days
Washout period: 7 days + 7 days baseline registration
Outcomes Outcomes
• Improvements in crying history
◦ Semi-structured interview (modified from Lawson and Macleod)
◦ Qualitative clinical evaluation of facial grimacing and concomitant crying
◦ Frequency of crying episodes (5-point scale; none to continuous)
◦ Context in which episodes occurred (3-point scale; non-specific to
emotionally provoked)
◦ Recorded quantitative or qualitative data concerning crying (kept in a diary)
• Unwanted side effects (UKU side effects rating scale)
• Compliance (examination of medical containers at the end of study)
Notes Unable to use in analysis: interviewer-assessed no longer meet criteria for emotionalism
- modified Lawson and Macleod scale, 50% reduction in emotionalism, HDRS, leaving
the study early, adverse events (data not reported in appropriate format)
Risk of bias
Bias Authors’ judgement Support for judgement
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Andersen 1993 (Continued)
Random sequence generation (selection
bias)
Low risk Comments: participants were randomised
in blocks of 4, sequence generated byLund-
beck
Allocation concealment (selection bias) Low risk Comments: method of concealment was
centralised
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “We investigated the effect of the se-
lective serotonin reuptake inhibitor citalo-
pram on uncontrolled crying in stroke pa-
tients in a double-blind placebo-controlled
crossover study” pp. 837
Comments: the study authors stated that it
is a double-blinded trial but no details of
who were blinded were provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “We investigated the effect of the se-
lective serotonin reuptake inhibitor citalo-
pram on uncontrolled crying in stroke pa-
tients in a double-blind placebo-controlled
crossover study” pp. 837
Comments: the study authors stated that it
is a double-blinded trial but no details of
who were blinded were provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “1 of the patientswith classic patho-
logical crying (no 8) was withdrawn from
study during the initial treatment period
(placebo) because of a generalised seizure
on day 28; 2 others (no 3 and no 9) did
not complete the second treatment period
(both placebo) because of lack of response
to treatment after the first week” pp. 838
“In the latter cases the self-registered score
in the first week was therefore used as the
endpoint score” pp. 838
Comments: Dropouts or exclusions were
detailed. Reason for dropouts or exclusions
not related to group allocation. Method of
how they dealt with the dropouts were pro-
vided
Selective reporting (reporting bias) Low risk Comments: All prespecified outcomeswere
reported. No trial protocol available prior
to randomisation of first participant
Other bias Unclear risk Comments: No other bias detected
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Brown 1998
Methods Study design: parallel, randomised controlled trial
Number of arms: 2
Experimental arm: fluoxetine 20 mg/day
Control arm: placebo
Analysis: per protocol; 1 withdrawn (treatment), excluded from analysis
Participants Georgraphical location: Scotland
Setting: Astley Ainslie Hospital
Number of participants: 20
Diagnosis: stroke, time from stroke to randomisation not reported
Inclusion criteria: 1) following a stroke who had a history of emotionalism at least 4
weeks’ duration
Exclusion criteria: 1) cognitive impairment, 2) dysphasia, 3) major depressive disorder
Age: overall mean age not reported
Numbers included in treatment group: 10 participants (55% men, mean age 61.4 years,
SD 8.6)
Numbers included in control group: 10 participants (60% men, mean age 63.7 years,
SD 5.4)
Emotionalism criteria: emotionalism of at least 4 weeks duration assessed during semi-
structured interview using a modified Lawson and MacLeod rating scale, in addition to
frequency of outbursts
Interventions Treatment: fluoxetine 20 mg/day
Control: matched placebo
Duration: treatment continued for 10 days
Outcomes Outcomes
• Emotional outburst grade (modified Lawson and Macleod gradings)
• Depression (HDRS)
• Cognitive functioning (MMSE)
• Side effects (24-item checklist of possible symptoms)
Notes Able to use in analysis
• 50% reduction in frequency of emotionalism outbursts
• Leaving the study early
Unable to use in analysis: HDRS, Lawson and Macleod Scale, self-rating scales (mean
and SD not presented)
Adverse events (data not presented)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The patients were randomly allo-
cated by an independent statistician…”pp.
456
Comments: participants were randomly al-
located. Method of allocation not detailed
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Brown 1998 (Continued)
Allocation concealment (selection bias) Low risk Quote: “Themedicationwas repackaged so
as to make the active and placebo capsules
identical to each other” pp. 456
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The patients, nursing staff and rat-
ing clinicians were blinded to the allocation
of active or placebo medication” pp. 456
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The patients, nursing staff and rat-
ing clinicians were blinded to the allocation
of active or placebo medication” pp. 456
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “One patient had to be withdrawn
because he developed a generalised rash on
active …” pp. 456
Comments: dropouts or exclusions were
detailed. Reason for dropouts or exclusions
not related to group allocation
Selective reporting (reporting bias) Low risk Comments: all prespecified outcomes re-
ported. No trial protocol available prior to
randomisation of first participant
Other bias Unclear risk Comments: no other bias detected
Burns 1999
Methods Study design: parallel, randomised controlled trial
Number of arms: 2
Experimental arm: sertraline 50 mg/day
Control arm: placebo
Analysis: intention-to-treat: 2 withdrawn and 1 death (treatment), 1 death (placebo),
last value carried forward
Participants Geographical location: UK
Setting: 3 hospitals in Manchester
Number of participants: 28
Diagnosis: stroke, 1 to 156 months prior to randomisation
Inclusion criteria: 1) clinically documented stroke (with or without computed tomog-
raphy evidence of infarction), 2) presence of lability of mood observed by the referring
clinician, 3) at least 1 month having elapsed since stroke, 4) absence of depression and
dementia according to DSM-III-R criteria
Exclusion criteria: 1) less than 1 month since stroke, 2) depression or dementia using
DSM-III-R criteria
Age: overall mean age not reported
Numbers included in treatment group: 14 (36% men, mean age 73 years, SD 9.1)
Numbers included in control group: 14 (57% men, mean age 67.6 years, SD 8.5)
Emotionalism criteria: lability of mood observed by referring clinician
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Burns 1999 (Continued)
Interventions Treatment: sertraline 50 mg/day
Control: matched placebo
Duration: treatment continued for 8 weeks
Outcomes Primary outcomes
• Emotionalism/Lability of mood (Lability scale, House 1989)
• Episodes of tearfulness (4-point rating scale; 0: 1 episode less than once per week;
1: episodes more than once a week but less than once a day; 2: episodes up to 5 times a
day; 3: episodes 6 or more times a day)
• CIBIC rating scale
Secondary outcomes
• Cognitive functioning (MMSE)
• Depression (MADRS)
• Physical functional ability (Barthel Index)
• Severity of stroke (Scandinavian Stroke Scale)
• Language dysfunction (Frenchay Aphasia Battery)
Notes Able to use in analysis
• Improved score on Lability scale (House 1989)
• Improved score on CIBIC
• Diminished tearfulness
• Leaving the study early
• Death
• Adverse events
Unable to use in analysis: MADRS, Barthel, MMSE (data not presented)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “After randomization (in blocks of
four using a random number allocation list
produced by the Department of Medical
Statistics…)” pp.683
Allocation concealment (selection bias) Unclear risk Comments: not detailed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “The study was carried out accord-
ing to a double-blind placebo controlled ..
.” pp. 683
Comments: the study authors stated that it
is a double-blinded trial but no details of
who were blinded were provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “The study was carried out accord-
ing to a double-blind placebo controlled ..
.” pp. 683
Comments: the study authors stated that it
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Burns 1999 (Continued)
is a double-blinded trial but no details of
who were blinded were provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Four patients did not complete the
study. Twowithdrew in the sertraline group
...” pp. 683
“Results are presented on an intention to
treat basis, with the last observation carried
forward….” pp. 683
Comments: dropouts or exclusions were
detailed. Reason for dropouts or exclusions
not related to group allocation. Method of
how they dealt with the dropouts were pro-
vided
Selective reporting (reporting bias) Low risk Comments: all prespecified outcomes re-
ported. No trial protocol available prior to
randomisation of first participant
Other bias Unclear risk Comments: no other bias detected
Choi-Kwon 2006
Methods Study design: parallel design
Number of arms: 2
Experimental arm: fluoxetine 20 mg/day
Control arm: placebo
Analysis: intention-to-treat: 3 withdrawn (placebo), last value carried forward
Per protocol was also performed to investigate the consistency of the results
Participants Geographical location: South Korea
Setting: Asan Medical Centre
Number of participants: 92
Diagnosis: stroke, time from stoke to randomisation not reported
Inclusion criteria: not specified
Exclusion criteria: 1) did not undergo imaging (CT/MRI) studies, 2) had subarachnoid
haemorrhage, 3) had transient ischaemic attack without progression to stroke, 4) had
communication problems (aphasia, dementia or dysarthria) severe enough as not to
undergo a reliable interview, 5) were scored < 23 on MMSE, 6) had a history of being
diagnosed as having depression or other psychiatric illnesses before the onset of stroke,
7) had been already treated with psychiatric regimens including SSRI, and 8) lived alone
so that information from the relatives was not available
Age: mean age not reported
Numbers of included in treatment group: 44* - age and sex of participants with excessive
crying not reported
Numbers of included in control group: 48* - age and sex of participants with excessive
crying not reported
*Number stated is inconsistent in the report - we have reported data on excessive/
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Choi-Kwon 2006 (Continued)
inappropriate crying only, as represented in Table 3 of Choi-Kwon 2006
Emotionalism criteria: emotionalism is present if both patients and relatives agreed that
≥ 2 occasions of excessive or inappropriate laughing or crying or both has occurred as
compared with their premorbid state
Interventions Treatment: fluoxetine 20 mg/day
Control: matched placebo
Duration: treatment continued for 3 months
Assessments performed at enrolment, 1 month, 3 months, and 6 months
Outcomes Primary outcomes
• Presence poststroke depression (BDI score)
• Intenstiy of poststroke emotional incontinence (VAS)
• Presence of poststroke anger (Spielberger Trait Anger Scale)
Secondary outcomes
• Percentage changes in BDI scores for poststroke depression
• Percentage changes in VAS scores for emotional incontinence crying/laughing
• Percentage changes in poststroke anger scores
• Patients’ subjective responses as “aggravated”, “no change” and “improved”
Notes Able to use in analysis
• Patients’ subjective responses of improvement in excessive/inappropriate crying
• Leaving the study early
Unable to use in analysis: VAS formeasuring extent of excessive or inappropriate laughing
or crying (data not presented in appropriate format). Percentage change of VAS between
follow-ups (number of emotionalism participants is inconsistent in report)
Adverse events (data for emotionalism participants not stated)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Treatment allocation was based
on a computer generated list of treatment
numbers” pp.157
Allocation concealment (selection bias) Unclear risk Comments: not detailed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The patient, relatives and re-
searchers were not aware of the drug being
given” pp. 157
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The patient, relatives and re-
searchers were not aware of the drug being
given” pp. 157
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Among 152 patients, 27 dropped
out before completing the 3-month treat-
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Choi-Kwon 2006 (Continued)
ment protocol (15 received fluoxetine, and
12 received placebo), leaving 125 patients.
Although there was no difference in the
dropout rate between the 2 groups ...” pp.
157
Comments: number of total participants
stated is inconsistent
Selective reporting (reporting bias) Low risk Comments: all prespecified outcomes re-
ported. No trial protocol available prior to
randomisation of first participant
Other bias Unclear risk Comments: no other bias detected
Murray 2005
Methods Study design: parallel, randomised controlled trial
Number of arms: 2
Experimental arm: sertraline 50 mg/day to 100 mg/day
Control arm: placebo
Analysis: intention-to-treat: 8 withdrawn (treatment), 9 withdrawn and 1 deaths
(placebo), last value carried forward
Participants Geographical location: Sweden
Setting: 4 stroke centres throughout Sweden
Number of participants: 44
Diagnosis: stroke, and depression within 12 months after a stroke, 3 to 375 days prior
to randomization (mean of 128 ± 97 days)
Inclusion criteria: 1) with major depressive episode according to DSM-IV criteria, 2)
minor depressive disorder according to DSM-IV research criteria and a MADRS score
> 10
Exclusion criteria: 1) apparent difficulties in adhering to the study protocol, 2) severe
impairment of the ability to communicate, 3) acute myocardial infarction, 4) psychiatric
illnesses other than depression, 5) significant risk of suicide, 6) on antidepressant drug
treatment during the month before the study start, 7) current use of any psychotropic
medications (with the exception of small daytime doses of benzodiazepines or zopiclone,
zolpidem or benzodiazepines for night sedation), and 8) current use of opiate analgesic
drugs
Age: overall mean age not reported
Numbers of included in treatment group: 24 (58% men, mean age 69.5 years, SD 9.4)
Numbers of included in control group: 20 (30% men, mean age 65.9, SD 10.9)
Emotionalism criteria: increased tearfulness and pathological crying reported by patients
and relatives
Interventions Treatment: sertraline 50 to 100 mg daily (dosage was increased to 100 mg for patients
with lack of improvement after 4 weeks; intake reduced to the starting dose if side effects
occurred)
Control: matched placebo
Duration: treatment continued for 26 weeks
31Pharmaceutical interventions for emotionalism after stroke (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Murray 2005 (Continued)
Outcomes Primary outcome
• Change in MADRS
Secondary outcomes
• Response rate > 50% decrease in MADRS score
• Remission rate MADRS score < 1
Notes Able to use in analysis
• Presence or absence of emotionalism measured as a dichotomous variable
• MADRS
• Leaving the study early
• Death
• Limited adverse events
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A centralized randomization pro-
cedure was applied”. pp. 709
Allocation concealment (selection bias) Low risk Quote: “Each centre pharmacy received
a consecutive series of pre-sealed treat-
ment package. Patient received double-
blind identical capsules of either sertraline
...” pp. 709
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “This 26-week, double-blind,
placebo-controlled study of sertraline was
carried out ...”pp. 709
Comments: the study authors stated that it
is a double-blinded trial but no details of
who were blinded were provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “This 26-week, double-blind,
placebo-controlled study of sertraline was
carried out….”pp. 709
Comments: the study authors stated that it
is a double-blinded trial but no details of
who were blinded were provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “At week 6, 11 patients (18%) in
the sertraline group and6patients (10%) in
the placebo group had dropped out of the
study (Figure 2). At week 26, an additional
13 patients (21%) in the sertraline group
and 24 patients (39%) in the placebo group
had been withdrawn. Of the 54 patients
prematurely withdrawn, 30 had amajor de-
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Murray 2005 (Continued)
pressive episode and 17 a minor depressive
disorder. Lack of antidepressant effect was
the reason for exclusion in 38 cases and side
effects in 13”
Comments: dropouts or exclusions were
detailed. Reason for dropouts or exclusions
not related to group allocation. Method of
how they dealt with the dropouts were pro-
vided. Analysis was performed based on the
intention-to-treat principle
Selective reporting (reporting bias) Low risk Comments: all prespecified outcomes re-
ported. No trial protocol available prior to
randomisation of first participant
Other bias Unclear risk Comments: no other bias detected
Ohkawa 1989
Methods Study design: cross-over, randomised controlled trial
Number of arms: 2
Experimental arm: amitriptyline 50 mg/day
Control arm: bitter stomach medicine only
Analysis: per protocol: 2 withdrawn (treatment), 1 withdrawn (placebo), excluded from
analysis
Participants Geographical location: Japan
Setting: hospital setting
Number of participants: 10
Diagnosis: mixed vascular group with lacunar state, 1 month to 2 years prior to ran-
domisation
Inclusion criteria: not specified
Exclusion criteria: not specified
Age: mean age 63.3 years, SD 7.2, range 51 to 73 years
Sex: 86% male
Emotionalism criteria: compulsive laughter alone or with compulsive crying, definition
unclear
Interventions Treatment: amitriptyline 50 mg daily, mixed with bitter stomach medicine to disguise
taste and smell
Control: bitter stomach medicine only
Cross-over details: 3 weeks each of placebo and amitriptyline in random order
Duration: treatment continued for 3 weeks
Outcomes Outcomes
• Frequency of occurrence of compulsive laughter (classified into 4 classes: 0-none,
1-mild, only once, 2-moderate, a few times and 3-severe, frequent)
• Depression (Self-Rating Depression Scale)
• Cognitive functioning (MMSE)
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Notes Unable to use in analysis: no longer meet criteria for emotionalism, improved scores on
frequency of compulsive laughtermeasure, leaving the study early, Self-RatingDepression
Scale, MMSE (data not presented in appropriate format)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “... and placebowere dosed in a ran-
dom order (determined by the a controller
...” pp. 1184
Comments: method of randomisation not
detailed
Allocation concealment (selection bias) Unclear risk Comments: not detailed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “At examination, either the pa-
tients or nursing family members were in-
terviewed ...” pp. 1184
Comments: the study stated that it is a dou-
ble-blind placebo controlled trial
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The examiner (other author), to
whom the dosage order is unknown ...” pp.
1184
“Also a psychiatrist, to whom dosage is un-
known, performed the self-rating depres-
sion scale (SDS) ...” pp. 1184
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “At first ten subjects was selected
for the experiment, but three have been ex-
cluded ...” pp. 1184
Comments: dropouts or exclusions were
detailed. Reason for dropouts or exclusions
not related to group allocation
Selective reporting (reporting bias) Low risk Comments: all prespecified outcomes re-
ported. No trial protocol available prior to
randomisation of first participant
Other bias Unclear risk Comments: no other bias detected
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Robinson 1993b
Methods Study design: parallel, randomised controlled trial
Number of arms: 2
Experimental arm: nortriptyline
Control arm: placebo
Analysis: per protocol. 3 dropouts (treatment), excluded from analysis
Participants Geographical location: USA
Setting: university hospital
Number of participants: 29
Diagnosis: stroke, on average 8.1 (SD 9.9 treatment), 15.7 (SD 13.5 control) months
prior to randomisation
Inclusion criteria: not specified
Exclusion criteria: patients with decreased levels of consciousness or moderate to severe
aphasia with deficits in comprehension
Age: overall mean age not reported
Numbers included in treatment group: 15 (60% men, mean age 57.8 years, SD 10.1)
Numbers included in control group: 14 (40% men, mean age 58.5 years, SD 11.8)
Emotionalism criteria: score of > 12 on the PLCS
Interventions Treatment: nortriptyline, 1 week at 20 mg, 2 weeks at 50 mg, 1 week at 70 mg and 2
weeks at 100 mg
Control: matched placebo
Duration: treatment continued for 6 weeks
Outcomes Outcomes
• Emotionalism (PLCS scores)
• Depression (HDRS)
• Activities of Daily Living (John Hopkins Functioning Inventory)
• Cognitive functioning (MMSE)
Notes Able to use in analysis
• PLCS
• HDRS
• MMSE
• John Hopkins Functioning Inventory
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “... in a single daily dose at bedtime
after random number assignment ...” pp.
287
Allocation concealment (selection bias) Low risk Quote: “The 28 patients participating in
the treatment study were given nortripty-
line or placebo (in identical capsules) ...”
pp. 287
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Robinson 1993b (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Both the patients and the examin-
ers were unaware of which treatment was
being given.” pp. 287
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Both the patients and the examin-
ers were unaware of which treatment was
being given.” pp. 287
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “There was only one patient who
dropped out during the course of the
study”. pp. 287
“ ... dropped out between weeks 2 and 4
because of complaints of sedation.” pp. 287
Comments: dropouts or exclusions were
detailed. Reason for dropouts or exclusions
not related to group allocation
Selective reporting (reporting bias) Low risk Comments: all prespecified outcomes re-
ported. No trial protocol available prior to
randomisation of first participant
Other bias Unclear risk Comments: no other bias detected
BDI: Beck Depression Inventory
CIBIC: Clinician Interview-Based Impression of Change
CT: computerised tomography
HDRS: Hamilton Depression Rating Scale
MADRS: Montgomery Asberg Depression Rating Scale
MMSE: Mini Mental State Examination
MRI: magnetic resonance imaging
PLCS: Pathological Laughter and Crying Scale
SD: standard deviation
VAS: Visual Analogue Scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aizawa 1977 Methods: double-blind RCT
Participants: cerebrovascular disorders (including arteriosclerosis)
Intervention: cyclandelate for 4 weeks
Outcomes: data not currently available for those with ’emotionalism’ at baseline
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Allen 2018 Methods: not a RCT, i.e. non-interventional, cross-sectional, case control study
Participants: nursing home residents with documented diagnosis of pseudobulbar affect
Intervention: dextromethorphan/quinidine
Atarashi 1988 Methods: randomisation unclear
Participants: stroke, including cerebral arteriosclerosis
Intervention: no placebo comparison
Bassi 1984 Methods: non-random, open-label
Participants: chronic cerebrovascular disorders
Intervention: no placebo comparison
Chen 2010 Methods: not a RCT, i.e. case report and literature review
Intervention: quetiapine
Colamonico 2012 Methods: not a RCT, i.e. survey of to estimate the impact or burden of pseudobulbar affect
D’Amico 2017 Methods: non-random, open-label
Doody 2014 Participants: ineligible study population, i.e. participants were adults who had pseudobulbar affect after being
diagnosed with dementia/Alzheimer’s Disease
Formella 2017a Methods: non-random, open-label
Formella 2017b Methods: non-random, open-label
Kim 2017a Outcomes: data not currently available for those with ’emotionalism’ at baseline pretreatment
Kim 2017b Methods: not a RCT, i.e. review of the most common poststroke mood and emotional disturbances
Lawson 1969 Methods: randomised
Participants: hypertensive or ischaemic cerebral disease (number with stroke unclear)
Intervention: method of randomisation makes placebo comparison ineffectual - no appropriate washout period
Manzo 1998 Methods: not a RCT, i.e. qualitative study of pseudobulbar affect
Moller 2007 Methods: randomised
Participants: patients with stroke and pathological crying
Intervention: citalopram for 30 days
Outcomes: emotionalism not investigated
Muller 1999 Methods: quasi-randomised, 2 active treatments
Participants: brain injury
Intervention: no placebo comparison
Narushima 2002 Methods: double-blind, randomised
Participants: poststroke
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Intervention: prevention of depression
Outcomes: emotionalism not investigated
Ohtomo 1985 Methods: double-blind, randomised
Participants: cerebrovascular disorders, including arteriosclerosis
Intervention: tiapride for 5 weeks
Outcomes: data not currently available for those with ’emotionalism’ at baseline
Otomo 1984 Methods: double-blind, randomised
Participants: cerebrovascular disorders
Outcomes: emotionalism not investigated
Rasmussen 2000 Methods: double-blind, randomised
Participants: poststroke without depression, emotionalism not assessed at baseline
Sauve 2017 Participants: ineligible study population, i.e. participants were adults who had pseudobulbar affect after being
diagnosed with dementia/Alzheimer’s Disease
Schiffer 1985 Methods: double-blind, cross-over
Participants: ineligible study population, i.e. multiple sclerosis (not stroke)
Seliger 1992 Method: non-random, open-label
Participants: patients with stroke or multiple sclerosis (not stroke) and emotional incontinence
Udaka 1984 Methods: non-random, open-label
Participants: ineligible study population, i.e. diffuse cerebrovascular disease (not stroke)
Work 2011 Methods: not a RCT, i.e. a survey to estimate the overall prevalence of pseudobulbar affect and quantify the
extent to which it is diagnosed and treated
Yang 2015 Methods: not a RCT, i.e. a literature review
Participants: adults with pseudobulbar affect
Intervention: dextromethorphan/quinidine
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Pharmaceutical interventions versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Emotionalism 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 50% reduction in
emotionalism
1 19 Risk Ratio (M-H, Random, 95% CI) 16.5 [1.07, 253.40]
1.2 Improved score on Lability
scale (House 1989 measure)
1 28 Risk Ratio (M-H, Random, 95% CI) 1.44 [0.95, 2.19]
1.3 Clinician interview-
based impression of change -
improved score
1 28 Risk Ratio (M-H, Random, 95% CI) 1.44 [0.95, 2.19]
1.4 Diminished tearfulness 3 164 Risk Ratio (M-H, Random, 95% CI) 2.18 [1.29, 3.71]
2 Emotionalism: mean scores at
end of treatment
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Pathological Laughter
and Crying Scale (high score =
worse emotionalism)
1 28 Mean Difference (IV, Fixed, 95% CI) -8.4 [-11.56, -5.24]
3 Depression: 1. Mean scores at
end of treatment
2 72 Std. Mean Difference (IV, Random, 95% CI) -0.82 [-2.14, 0.51]
3.1 Hamilton Depression
Rating Scale (high score = more
depressed)
1 28 Std. Mean Difference (IV, Random, 95% CI) -1.53 [-2.39, -0.67]
3.2 Montgomery Asberg
Depression Rating Scale (high
score = more depressed)
1 44 Std. Mean Difference (IV, Random, 95% CI) -0.18 [-0.77, 0.42]
4 Depression: 2. Average change
in scores between baseline and
end of treatment
2 72 Std. Mean Difference (IV, Random, 95% CI) -0.05 [-0.72, 0.62]
4.1 Hamilton Depression
Rating Scale (high score = more
depressed)
1 28 Std. Mean Difference (IV, Random, 95% CI) -0.43 [-1.18, 0.32]
4.2 Montgomery Asberg
Depression Rating Scale (high
score = more depressed)
1 44 Std. Mean Difference (IV, Random, 95% CI) 0.26 [-0.34, 0.85]
5 Cognitive functioning: mean
scores at end of treatment
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 Mini-mental state
examination (low score =
cognitive impairment)
1 28 Mean Difference (IV, Fixed, 95% CI) -0.30 [-3.27, 2.67]
6 Activities of daily living: 1. Mean
scores at end of treatment
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 Johns Hopkins
Functioning Inventory (high
score = worse function)
1 28 Mean Difference (IV, Fixed, 95% CI) -1.40 [-5.22, 2.42]
7 Adverse events: 1. Death 6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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7.1 At end of treatment 6 172 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.08, 4.50]
8 Adverse events: 2. All 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Central nervous system
events (e.g. confusion, sedation,
tremor)
2 56 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.11, 9.08]
8.2 Gastrointestinal effects (e.
g. constipation, diarrhoea)
1 28 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.01, 7.55]
8.3 Other events not listed
above (e.g. dysuria, eye
discomfort)
1 28 Risk Ratio (M-H, Random, 95% CI) 5.0 [0.26, 95.61]
8.4 Recurrent stroke 1 28 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.07, 14.45]
9 Adverse events: 3. Leaving the
study early (including death)
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 All dropouts and
withdrawals
5 216 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.38, 3.58]
Analysis 1.1. Comparison 1 Pharmaceutical interventions versus placebo, Outcome 1 Emotionalism.
Review: Pharmaceutical interventions for emotionalism after stroke
Comparison: 1 Pharmaceutical interventions versus placebo
Outcome: 1 Emotionalism
Study or subgroup Intervention Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 50% reduction in emotionalism
Brown 1998 7/9 0/10 100.0 % 16.50 [ 1.07, 253.40 ]
Subtotal (95% CI) 9 10 100.0 % 16.50 [ 1.07, 253.40 ]
Total events: 7 (Intervention), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.044)
2 Improved score on Lability scale (House 1989 measure)
Burns 1999 13/14 9/14 100.0 % 1.44 [ 0.95, 2.19 ]
Subtotal (95% CI) 14 14 100.0 % 1.44 [ 0.95, 2.19 ]
Total events: 13 (Intervention), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.084)
3 Clinician interview-based impression of change - improved score
Burns 1999 13/14 9/14 100.0 % 1.44 [ 0.95, 2.19 ]
Subtotal (95% CI) 14 14 100.0 % 1.44 [ 0.95, 2.19 ]
Total events: 13 (Intervention), 9 (Placebo)
Heterogeneity: not applicable
0.002 0.1 1 10 500
Favours placebo Favours treatment
(Continued . . . )
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Study or subgroup Intervention Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 1.73 (P = 0.084)
4 Diminished tearfulness
Burns 1999 14/14 9/14 41.7 % 1.53 [ 1.03, 2.27 ]
Choi-Kwon 2006 37/44 14/48 38.6 % 2.88 [ 1.82, 4.56 ]
Murray 2005 13/24 4/20 19.7 % 2.71 [ 1.05, 7.01 ]
Subtotal (95% CI) 82 82 100.0 % 2.18 [ 1.29, 3.71 ]
Total events: 64 (Intervention), 27 (Placebo)
Heterogeneity: Tau2 = 0.13; Chi2 = 5.58, df = 2 (P = 0.06); I2 =64%
Test for overall effect: Z = 2.89 (P = 0.0038)
0.002 0.1 1 10 500
Favours placebo Favours treatment
Analysis 1.2. Comparison 1 Pharmaceutical interventions versus placebo, Outcome 2 Emotionalism: mean
scores at end of treatment.
Review: Pharmaceutical interventions for emotionalism after stroke
Comparison: 1 Pharmaceutical interventions versus placebo
Outcome: 2 Emotionalism: mean scores at end of treatment
Study or subgroup Intervention Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Pathological Laughter and Crying Scale (high score = worse emotionalism)
Robinson 1993b 14 1.2 (2) 14 9.6 (5.7) 100.0 % -8.40 [ -11.56, -5.24 ]
Subtotal (95% CI) 14 14 100.0 % -8.40 [ -11.56, -5.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.20 (P < 0.00001)
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Analysis 1.3. Comparison 1 Pharmaceutical interventions versus placebo, Outcome 3 Depression: 1. Mean
scores at end of treatment.
Review: Pharmaceutical interventions for emotionalism after stroke
Comparison: 1 Pharmaceutical interventions versus placebo
Outcome: 3 Depression: 1. Mean scores at end of treatment
Study or subgroup Intervention Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Hamilton Depression Rating Scale (high score = more depressed)
Robinson 1993b 14 2.1 (2.4) 14 11.3 (7.9) 47.3 % -1.53 [ -2.39, -0.67 ]
Subtotal (95% CI) 14 14 47.3 % -1.53 [ -2.39, -0.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.50 (P = 0.00047)
2 Montgomery Asberg Depression Rating Scale (high score = more depressed)
Murray 2005 24 7.67 (6.56) 20 9.09 (9.14) 52.7 % -0.18 [ -0.77, 0.42 ]
Subtotal (95% CI) 24 20 52.7 % -0.18 [ -0.77, 0.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
Total (95% CI) 38 34 100.0 % -0.82 [ -2.14, 0.51 ]
Heterogeneity: Tau2 = 0.77; Chi2 = 6.45, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Chi2 = 6.45, df = 1 (P = 0.01), I2 =84%
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Analysis 1.4. Comparison 1 Pharmaceutical interventions versus placebo, Outcome 4 Depression: 2.
Average change in scores between baseline and end of treatment.
Review: Pharmaceutical interventions for emotionalism after stroke
Comparison: 1 Pharmaceutical interventions versus placebo
Outcome: 4 Depression: 2. Average change in scores between baseline and end of treatment
Study or subgroup Intervention Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Hamilton Depression Rating Scale (high score = more depressed)
Robinson 1993b 14 -10 (5.43) 14 -7.3 (6.69) 44.3 % -0.43 [ -1.18, 0.32 ]
Subtotal (95% CI) 14 14 44.3 % -0.43 [ -1.18, 0.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
2 Montgomery Asberg Depression Rating Scale (high score = more depressed)
Murray 2005 24 -10.71 (6.31) 20 -12.61 (8.206) 55.7 % 0.26 [ -0.34, 0.85 ]
Subtotal (95% CI) 24 20 55.7 % 0.26 [ -0.34, 0.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.40)
Total (95% CI) 38 34 100.0 % -0.05 [ -0.72, 0.62 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 1.98, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Chi2 = 1.98, df = 1 (P = 0.16), I2 =50%
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Analysis 1.5. Comparison 1 Pharmaceutical interventions versus placebo, Outcome 5 Cognitive
functioning: mean scores at end of treatment.
Review: Pharmaceutical interventions for emotionalism after stroke
Comparison: 1 Pharmaceutical interventions versus placebo
Outcome: 5 Cognitive functioning: mean scores at end of treatment
Study or subgroup Intervention Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mini-mental state examination (low score = cognitive impairment)
Robinson 1993b 14 26.5 (4.8) 14 26.8 (3) 100.0 % -0.30 [ -3.27, 2.67 ]
Subtotal (95% CI) 14 14 100.0 % -0.30 [ -3.27, 2.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
-10 -5 0 5 10
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Analysis 1.6. Comparison 1 Pharmaceutical interventions versus placebo, Outcome 6 Activities of daily
living: 1. Mean scores at end of treatment.
Review: Pharmaceutical interventions for emotionalism after stroke
Comparison: 1 Pharmaceutical interventions versus placebo
Outcome: 6 Activities of daily living: 1. Mean scores at end of treatment
Study or subgroup Intervention Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Johns Hopkins Functioning Inventory (high score = worse function)
Robinson 1993b 14 3.7 (5) 14 5.1 (5.3) 100.0 % -1.40 [ -5.22, 2.42 ]
Subtotal (95% CI) 14 14 100.0 % -1.40 [ -5.22, 2.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
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Analysis 1.7. Comparison 1 Pharmaceutical interventions versus placebo, Outcome 7 Adverse events: 1.
Death.
Review: Pharmaceutical interventions for emotionalism after stroke
Comparison: 1 Pharmaceutical interventions versus placebo
Outcome: 7 Adverse events: 1. Death
Study or subgroup Intervention Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 At end of treatment
Andersen 1993 0/16 0/16 Not estimable
Brown 1998 0/10 0/10 Not estimable
Burns 1999 1/14 1/14 58.1 % 1.00 [ 0.07, 14.45 ]
Murray 2005 0/24 1/20 41.9 % 0.28 [ 0.01, 6.52 ]
Ohkawa 1989 0/10 0/10 Not estimable
Robinson 1993b 0/14 0/14 Not estimable
Subtotal (95% CI) 88 84 100.0 % 0.59 [ 0.08, 4.50 ]
Total events: 1 (Intervention), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
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Analysis 1.8. Comparison 1 Pharmaceutical interventions versus placebo, Outcome 8 Adverse events: 2. All.
Review: Pharmaceutical interventions for emotionalism after stroke
Comparison: 1 Pharmaceutical interventions versus placebo
Outcome: 8 Adverse events: 2. All
Study or subgroup Intervention Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Central nervous system events (e.g. confusion, sedation, tremor)
Burns 1999 0/14 1/14 50.0 % 0.33 [ 0.01, 7.55 ]
Robinson 1993b 1/14 0/14 50.0 % 3.00 [ 0.13, 67.91 ]
Subtotal (95% CI) 28 28 100.0 % 1.00 [ 0.11, 9.08 ]
Total events: 1 (Intervention), 1 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.95, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
2 Gastrointestinal effects (e.g. constipation, diarrhoea)
Burns 1999 0/14 1/14 100.0 % 0.33 [ 0.01, 7.55 ]
Subtotal (95% CI) 14 14 100.0 % 0.33 [ 0.01, 7.55 ]
Total events: 0 (Intervention), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
3 Other events not listed above (e.g. dysuria, eye discomfort)
Burns 1999 2/14 0/14 100.0 % 5.00 [ 0.26, 95.61 ]
Subtotal (95% CI) 14 14 100.0 % 5.00 [ 0.26, 95.61 ]
Total events: 2 (Intervention), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
4 Recurrent stroke
Burns 1999 1/14 1/14 100.0 % 1.00 [ 0.07, 14.45 ]
Subtotal (95% CI) 14 14 100.0 % 1.00 [ 0.07, 14.45 ]
Total events: 1 (Intervention), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
0.005 0.1 1 10 200
Favours treatment Favours placebo
46Pharmaceutical interventions for emotionalism after stroke (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.9. Comparison 1 Pharmaceutical interventions versus placebo, Outcome 9 Adverse events: 3.
Leaving the study early (including death).
Review: Pharmaceutical interventions for emotionalism after stroke
Comparison: 1 Pharmaceutical interventions versus placebo
Outcome: 9 Adverse events: 3. Leaving the study early (including death)
Study or subgroup Intervention Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 All dropouts and withdrawals
Brown 1998 1/10 0/10 10.7 % 3.00 [ 0.14, 65.90 ]
Burns 1999 3/14 1/14 18.6 % 3.00 [ 0.35, 25.46 ]
Choi-Kwon 2006 0/44 3/48 11.6 % 0.16 [ 0.01, 2.93 ]
Murray 2005 8/24 10/20 46.8 % 0.67 [ 0.33, 1.36 ]
Robinson 1993b 4/18 0/14 12.2 % 7.11 [ 0.41, 121.88 ]
Subtotal (95% CI) 110 106 100.0 % 1.17 [ 0.38, 3.58 ]
Total events: 16 (Intervention), 14 (Placebo)
Heterogeneity: Tau2 = 0.56; Chi2 = 6.09, df = 4 (P = 0.19); I2 =34%
Test for overall effect: Z = 0.27 (P = 0.78)
0.01 0.1 1 10 100
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A D D I T I O N A L T A B L E S
Table 1. Characteristics of ’dropout’ studies
Study ID Methods Participants Interventions Outcomes Notes
Aizawa 1977 Study design:
randomised, par-
allel design
Number of arms:
2
Arm 1: cyclande-
late 900 mg/day
+ cinnarizine 75
mg/day
Arm 2: placebo
+ cinnarizine 75
mg/day
Analysis: per pro-
Georgraphical
location: Japan
Setting: 50 insti-
tutes across
South Korea
Number of par-
ticipants: 378
Diagnosis: stroke
over one month
ago
Inclusion crite-
ria: 1) inpatients
and outpatients
Arm 1: cyclan-
delate 900 mg/
day and cinnar-
izine 75 mg/day
Arm 2: matched
placebo and cin-
narizine 75 mg/
day
Duration: treat-
ment continued
for 4 weeks
• Global
improvement
rating
• Improvement
rating of
subjective
symptoms
• Improvement
rating of
psychiatric
Unable to
use: all data (data
not presented by
’emotionalism at
baseline’, unable
to exclude people
with cerebral ar-
teriosclerosis and
transient
ischaemic attack)
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Table 1. Characteristics of ’dropout’ studies (Continued)
tocol who had cerebral
infarct, intracra-
nial bleeding,
transient cerebral
ischaemia
and cerebral arte-
riosclerosis
Exclusion crite-
ria: 1) expectant
mothers; 2) with
glaucoma and 3)
severe concomi-
tant diseases
Age:
overall mean age
not reported
Num-
bers included in
Arm1: 188 (68%
men, age details
unclear)
Num-
bers included in
Arm2: 190 (68%
men, age details
unclear)
symptoms
• Improvement
rating of
neurological
symptoms
• Global
utility rating
• Overall
safety rating
Ohtomo 1985 Study design:
randomised, par-
allel design
Number of arms:
2
Arm 1: tiapride
75 mg/day for 1
week, dose esca-
lation to 150 to
225 mg/day for
5 weeks accord-
ing to clinical re-
sponse
Arm 2: placebo
+ cinnarizine 75
mg/day
Analysis: per pro-
tocol
Geographical lo-
cation: Japan
Setting: unclear
Number of par-
ticipants: 188
Diagnosis:
cerebral haemor-
rhage, sub-
arachnoid haem-
orrhage, cerebral
infarction, cere-
bral apoplexy se-
quelae, cerebral
arteriosclerosis
Inclusion cri-
teria: 1) patients
with cerebral ar-
teriosclerosis
Exclu-
sion criteria: 1)
severe aphasia, 2)
severe dementia,
Arm 1: tiapride
75 mg/day for 1
week, dose esca-
lation to 150 to
225 mg/day for
5 weeks accord-
ing to clinical re-
sponse
Arm 2: matched
placebo
Duration: treat-
ment continued
for 6 weeks
• Severity of
psychiatric
symptoms
• Activities of
daily living
• Somatic
complaints
Unable to
use: all data (data
not presented by
’emotionalism at
baseline’, unable
to exclude people
with cerebral ar-
teriosclerosis)
48Pharmaceutical interventions for emotionalism after stroke (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Characteristics of ’dropout’ studies (Continued)
3) drug depen-
dence, 4) inade-
quate conditions
for the study
Age:
overall mean age
not reported
Num-
bers included in
Arm1: 141 (54%
men, age details
unclear)
Num-
bers included in
Arm2: 147 (61%
men, age details
unclear)
Kim 2017a Study design:
randomised, par-
allel design
Number of arms:
2
Arm 1: escitalo-
pram 10 mg/day
Arm 2: placebo
Analysis: per pro-
tocol
Geographical lo-
cation: South
Korea
Set-
ting: 17 hospitals
across South Ko-
rea
Number of par-
ticipants: 478
Diagno-
sis: stroke, had an
acute ischaemic
stroke or intrac-
erebral haemor-
rhage within the
previous 21 days
(confirmed by
MRI or CT)
Inclusion
criteria: 1) > 20
years, 2) had an
acute ischaemic
stroke or intrac-
erebral haemor-
rhage within the
previous 21 days
(confirmed by
MRI or CT), 3)
modified Rankin
Scale score > 2
Arm 1: escitalo-
pram 10 mg/day
Arm 2: matched
placebo
Duration: 12
weeks
Primary
outcomes:
• occurrence
of moderate or
severe depressive
symptoms
Secondary
outcomes:
• occurrence
of emotional
incontinence
(Kim’s criteria)
• anger
proneness
(modified
Spielberger trait
anger scale/
National
Institutes of
Health Stroke
Scale scores)
• modified
Rankin Scale
• Barthel
Index
Unable to use: all
data (data pre-
sented by ’emo-
tionalism at base-
line’ 1 month
post-treatment)
49Pharmaceutical interventions for emotionalism after stroke (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Characteristics of ’dropout’ studies (Continued)
Exclusion crite-
ria: 1) history of
diagnosed
depression or
other psychiatric
diseases before
the index stroke;
2) severe demen-
tia, 3) aphasia, 4)
exhibited strong
suicidal thoughts
Age:
overall mean age
not reported
Numbers in-
cluded in Arm 1:
210 (57% men,
mean age 64 (13)
years
Numbers in-
cluded in Arm 2:
195 (65% men,
mean age 64 (12)
years
CT: computerised tomography
MRI: magnetic resonance imaging
A P P E N D I C E S
Appendix 1. 2008 search strategy
Electronic searches
Cochrane Stroke and Cochrane Anxiety and Neurosis trial registers- searched on August 2009.
The remaining databases were searched on May 2008:
1. Cochrane Central Register for Controlled Trials
2. MEDLINE
3. Embase
4. CINAHL
5. PsycINFO
6. Applied Science and Technology Plus
7. Arts and Humanities Index
8. Biological Abstracts
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9. BIOSIS Previews
10. General Science Plus
11. Science Citation Index
12. Social Science Citation Index
13. Sociological Abstract/SocioFile
14. ISI Web of Science
15. Dissertations and Theses
The following search strategy with a combination of controlled vocabulary and free test terms for MEDLINE (Ovid) was used and
adapted it for the other databases.
1. cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp brain ischemia/ or exp carotid artery diseases/ or exp
intracranial arterial diseases/ or exp “intracranial embolism and thrombosis”/ or exp intracranial hemorrhages/ or stroke/ or exp brain
infarction/ or vasospasm, intracranial/ or vertebral artery dissection/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma$
or hematoma$ or bleed$)).tw.
5. 1 or 2 or 3 or 4
6. crying/ or laughter/
7. affective symptoms/ or emotions/
8. (laugh$ or cry$ or weep or weeping or emotional$ or pseudobulbar affect).tw.
9. 6 or 7 or 8
10. Randomized Controlled Trials as Topic/
11. random allocation/
12. Controlled Clinical Trials as Topic/
13. control groups/
14. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or
clinical trials, phase iv as topic/
15. double-blind method/
16. single-blind method/
17. Placebos/
18. placebo effect/
19. cross-over studies/
20. Multicenter Studies as Topic/
21. Therapies, Investigational/
22. Drug Evaluation/
23. Research Design/
24. Program Evaluation/
25. evaluation studies as topic/
26. randomized controlled trial.pt.
27. controlled clinical trial.pt.
28. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.
29. multicenter study.pt.
30. (evaluation studies or comparative study).pt.
31. meta analysis.pt.
32. meta-analysis as topic/
33. random$.tw.
34. (controlled adj5 (trial$ or stud$)).tw.
35. (clinical$ adj5 trial$).tw.
36. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
37. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
38. ((multicenter or multicentre or therapeutic) adj5 (trial$ or stud$)).tw.
39. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
40. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
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41. (coin adj5 (flip or flipped or toss$)).tw.
42. latin square.tw.
43. versus.tw.
44. (cross-over or cross over or crossover).tw.
45. placebo$.tw.
46. sham.tw.
47. (assign$ or alternate or allocat$ or counterbalance$ or multiple baseline).tw.
48. controls.tw.
49. (treatment$ adj6 order).tw.
50. (meta-analy$ or metaanaly$ or meta analy$ or systematic review or systematic overview).tw.
51. or/10-50
52. 5 and 9 and 51
53. limit 52 to humans
54. limit 53 to yr=“2002 - 2008”
Additional searches
We searched the following conference abstracts and proceedings:
• European Stroke Conferences (2000 to 2008);
• Stroke Society of Australasia Annual Scientific Meetings (1999 to 2008).
We also searched online clinical trials and research registers in May 2008:
• www.strokecenter.org/trials;
• www.ClinicalTrials.gov;
• www.Clinicalstudyresults.org;
• www.anzctr.org.au.
Reference lists
Reference lists of relevant studies were searched to identify studies not already included.
Personal communication
Professional bodies, authors of included studies and pharmaceutical companies were contacted for information on published and
unpublished information.
Appendix 2. CENTRAL
ID Search
#1 [mh ˆ“cerebrovascular disorders”] or [mh “basal ganglia cerebrovascular disease”] or [mh “brain ischemia”] or [mh “carotid
artery diseases”] or [mh “intracranial arterial diseases”] or [mh “intracranial arteriovenous malformations”] or [mh “intracranial
embolism and thrombosis”] or [mh “intracranial hemorrhages”] or [mh ˆstroke] or [mh “brain infarction”] or [mh ˆ“stroke,
lacunar”] or [mh ˆ“vasospasm, intracranial”] or [mh ˆ“vertebral artery dissection”] or [mh ˆ“brain injuries”] or [mh ˆ“brain
injury, chronic”]
#2 (stroke or poststroke or post-stroke or cerebrovasc* or brain next vasc* or cerebral next vasc* or cva* or apoplex* or SAH):ti,
ab,kw (Word variations have been searched)
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(Continued)
#3 ((brain* or cerebr* or cerebell* or intracran* or intracerebral) near/5 (isch*emi* or infarct* or thrombo* or emboli* or occlus*)
):ti,ab,kw (Word variations have been searched)
#4 ((brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid) near/5 (haemorrhage* or hemorrhage* or
haematoma* or hematoma* or bleed*)):ti,ab,kw (Word variations have been searched)
#5 {or #1-#4}
#6 [mh ˆcrying] or [mh ˆlaughter]
#7 [mh ˆ“affective symptoms”] or [mh êmotions]
#8 emotion* or laugh* or cry* or weep* or tearful* or pseudobulbar affect:ti,ab,kw (Word variations have been searched)
#9 {or #6-#8}
#10 #5 and #9 Publication Year from 2008 to 2018
Search results: 106
Appendix 3. MEDLINE
Search strategy for MEDLINE, May 2018
1. cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp brain ischemia/ or exp carotid artery diseases/ or exp
intracranial arterial diseases/ or exp “intracranial embolism and thrombosis”/ or exp intracranial hemorrhages/ or stroke/ or exp brain
infarction/ or vasospasm, intracranial/ or vertebral artery dissection/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma$
or hematoma$ or bleed$)).tw.
5. 1 or 2 or 3 or 4
6. crying/ or laughter/
7. affective symptoms/ or exp emotions/
8. (laugh$ or cry$ or weep$ or emotional$ or pseudobulbar affect).tw.
9. 6 or 7 or 8
10. Randomized Controlled Trials as Topic/
11. random allocation/
12. Controlled Clinical Trials as Topic/
13. control groups/
14. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or
clinical trials, phase iv as topic/
15. double-blind method/
16. single-blind method/
17. Placebos/
18. placebo effect/
19. cross-over studies/
20. randomized controlled trial.pt.
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21. controlled clinical trial.pt.
22. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.
23. (random$ or RCT or RCTs).tw.
24. (controlled adj5 (trial$ or stud$)).tw.
25. (clinical$ adj5 trial$).tw.
26. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
27. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
28. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
29. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
30. (cross-over or cross over or crossover).tw.
31. (placebo$ or sham).tw.
32. trial.ti.
33. (assign$ or allocat$).tw.
34. controls.tw.
35. or/10-34
36. exp animals/ not humans.sh.
37. 5 and 9 and 35
38. 37 not 36
Search results: 179
Appendix 4. Embase
Search strategy for Embase, May 2018
1. cerebrovascular disease/ or brain disease/ or exp basal ganglion hemorrhage/ or exp brain hemangioma/ or exp brain hematoma/
or exp brain hemorrhage/ or exp brain infarction/ or exp brain ischemia/ or exp carotid artery disease/ or exp cerebral artery disease/
or exp cerebrovascular accident/ or exp cerebrovascular malformation/ or exp intracranial aneurysm/ or exp occlusive cerebrovascular
disease/ or exp vertebrobasilar insufficiency/
2. (stroke$ or poststroke or apoplex$ or cerebral vasc$ or brain vasc$ or cerebrovasc$ or cva$ or SAH).tw.
3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or
middle cerebral artery or MCA$ or anterior circulation or posterior circulation or basilar artery or vertebral artery or space-occupying)
adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or intraparenchymal or intraventricular or infratentorial
or supratentorial or basal gangli$ or putaminal or putamen or posterior fossa or hemispher$ or subarachnoid) adj5 (h?emorrhag$ or h?
ematoma$ or bleed$)).tw.
5. 1 or 2 or 3 or 4
6. crying/ or pathological crying/ or laughter/ or pathological laughter/ or nonverbal communication/
7. emotion/ or affective neurosis/
8. emotional stability/ or emotionality/
9. (emotion$ or laugh$ or cry$ or weep$ or tearful$ or pseudobulbar affect).tw.
10. 6 or 7 or 8 or 9
11. Randomized Controlled Trial/ or “randomized controlled trial (topic)”/
12. Randomization/
13. Controlled clinical trial/ or “controlled clinical trial (topic)”/
14. control group/ or controlled study/
15. clinical trial/ or “clinical trial (topic)”/ or phase 1 clinical trial/ or phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical
trial/
16. Crossover Procedure/
17. Double Blind Procedure/
18. Single Blind Procedure/ or triple blind procedure/
19. placebo/ or placebo effect/
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20. (random$ or RCT or RCTs).tw.
21. (controlled adj5 (trial$ or stud$)).tw.
22. (clinical$ adj5 trial$).tw.
23. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
24. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
25. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
26. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
27. (cross-over or cross over or crossover).tw.
28. (placebo$ or sham).tw.
29. trial.ti.
30. (assign$ or allocat$).tw.
31. controls.tw.
32. or/11-31
33. (exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/) not
(human/ or normal human/ or human cell/)
34. 5 and 10 and 32
35. 34 not 33
Search results: 644
Appendix 5. CINAHL
Search strategy for CINAHL, May 2018
# Query
S1 (MH“Cerebrovascular Disorders”) OR (MH“Basal Ganglia Cerebrovascular Disease+”) OR (MH“Carotid ArteryDiseases+”)
OR (MH “Cerebral Ischemia+”) OR (MH “Cerebral Vasospasm”) OR (MH “Intracranial Arterial Diseases+”) OR (MH
“Intracranial Embolism and Thrombosis”) OR (MH “Intracranial Hemorrhage+”) OR (MH “Stroke”) OR (MH “Vertebral
Artery Dissections”)
S2 (MH “Stroke Patients”) OR (MH “Stroke Units”)
S3 TI (stroke* or poststroke or apoplex* or cerebral vasc* or brain vasc* or cerebrovasc* or cva* or SAH ) or AB ( stroke* or
poststroke or apoplex* or cerebral vasc* or brain vasc* or cerebrovasc* or cva* or SAH)
S4 TI (brain or cerebr* or cerebell* or vertebrobasil* or hemispher* or intracran* or intracerebral or infratentorial or supratentorial
or middle cerebral artery or MCA* or anterior circulation or posterior circulation or basilar artery or vertebral artery or space-
occupying ) or AB ( brain or cerebr* or cerebell* or vertebrobasil* or hemispher* or intracran* or intracerebral or infratentorial
or supratentorial or middle cerebral artery or MCA* or anterior circulation or posterior circulation or basilar artery or vertebral
artery or space-occupying)
S5 TI (ischemi* or ischaemi* or infarct* or thrombo* or emboli* or occlus* or hypoxi* ) or AB ( ischemi* or ischaemi* or infarct*
or thrombo* or emboli* or occlus* or hypox*)
S6 S4 and S5
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(Continued)
S7 TI (brain* or cerebr* or cerebell* or intracerebral or intracran* or parenchymal or intraparenchymal or intraventricular or
infratentorial or supratentorial or basal gangli* or putaminal or putamen or posterior fossa or hemispher* or subarachnoid)
or AB (brain* or cerebr* or cerebell* or intracerebral or intracran* or parenchymal or intraparenchymal or intraventricular or
infratentorial or supratentorial or basal gangli* or putaminal or putamen or posterior fossa or hemispher* or subarachnoid)
S8 TI (haemorrhage* or hemorrhage* or haematoma* or hematoma* or bleed* ) or AB ( haemorrhage* or hemorrhage* or
haematoma* or hematoma* or bleed*)
S9 S7 and S8
S10 S1 OR S2 OR S3 OR S6 OR S9
S11 (MH “Emotions+”) OR (MH “Affective Symptoms+”)
S12 (MH “Laughter”) OR (MH “Crying”) OR (MH “Nonverbal Communication”)
S13 TI ((laugh* or cry* or weep* or emotional* or pseudobulbar affect) ) OR AB ( (laugh* or cry* or weep* or emotional* or
pseudobulbar affect))
S14 S11 OR S12 OR S13
S15 (MH “Randomized Controlled Trials”) or (MH “Random Assignment”) or (MH “Random Sample+”)
S16 (MH “Clinical Trials”) or (MH “Intervention Trials”) or (MH “Therapeutic Trials”)
S17 (MH “Control (Research)”) or (MH “Control Group”) or (MH “Placebos”) or (MH “Placebo Effect”)
S18 (MH “Crossover Design”) OR (MH “Quasi-Experimental Studies”)
S19 (MH “Crossover Design”) OR (MH “Quasi-Experimental Studies”)
S20 PT (clinical trial or randomized controlled trial)
S21 TI (random* or RCT or RCTs) or AB (random* or RCT or RCTs)
S22 TI (controlled N5 (trial* or stud*)) or AB (controlled N5 (trial* or stud*))
S23 TI (clinical* N5 trial*) or AB (clinical* N5 trial*)
S24 TI ((control or treatment or experiment* or intervention) N5 (group* or subject* or patient*)) or AB ((control or treatment
or experiment* or intervention) N5 (group* or subject* or patient*))
Search results: 148
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Appendix 6. PsycINFO
Search strategy for PsycINFO, May 2018
1. cerebrovascular disorders/ or cerebral hemorrhage/ or exp cerebral ischemia/ or cerebral small vessel disease/ or cerebrovascular
accidents/ or subarachnoid hemorrhage/
2. (stroke$ or poststroke or apoplex$ or cerebral vasc$ or brain vasc$ or cerebrovasc$ or cva$ or SAH).tw.
3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or
middle cerebral artery or MCA$ or anterior circulation or posterior circulation or basilar artery or vertebral artery or space-occupying)
adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or intraparenchymal or intraventricular or infratentorial
or supratentorial or basal gangli$ or putaminal or putamen or posterior fossa or hemispher$ or subarachnoid) adj5 (h?emorrhag$ or h?
ematoma$ or bleed$)).tw.
5. hemiparesis/ or hemiplegia/
6. (hemipleg$ or hemipar$ or paresis or paraparesis or paretic).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp emotions/ or emotional adjustment/ or emotional stability/ or emotional instability/ or “resilience (psychological)”/ or exp
emotional responses/ or “emotionality (personality)”/ or emotional states/ or emotional adjustment/ or emotional control/ or emotionally
disturbed/
9. “crying/ or laughter/ or nonverbal communication/ or distress/”
10. (emotion$ or laugh$ or cry$ or weep$ or tearful$ or pseudobulbar affect).tw.
11. 8 or 9 or 10
12. clinical trials/ or treatment effectiveness evaluation/ or placebo/
13. (random$ or RCT or RCTs).tw.
14. (controlled adj5 (trial$ or stud$)).tw.
15. (clinical$ adj5 trial$).tw.
16. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
17. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
18. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
19. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
20. (cross-over or cross over or crossover).tw.
21. (placebo$ or sham).tw.
22. trial.ti.
23. (assign$ or allocat$).tw.
24. controls.tw.
25. or/12-24
26. 7 and 11 and 25
Search results: 54
Appendix 7. BIOSIS Previews
Search strategy for BIOSIS, May 2018
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# Query
S1 TS=(stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* or cerebral vasc* or cva* or apoplex* or SAH)
S2 TS=((brain* or cerebr* or cerebell* or intracran* or intracerebral) NEAR/5 (isch$emi* or infarct* or thrombo* or emboli* or
occlus*))
S3 TS=((brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid) NEAR/5 (haemorrhage* or hemorrhage*
or haematoma* or hematoma* or bleed*))
S4 #3 OR #2 OR #1
S5 TS=(emotion* or laugh* or cry* or weep* or tearful* or pseudobulbar affect)
S6 TS=(random* or RCT or RCTs)
S7 TS=(controlled NEAR/5 (trial* or stud*))
S8 TS=(clinical* NEAR/5 trial*)
S9 TS=((control or treatment or experiment* or intervention) NEAR/5 (group* or subject* or patient*))
S10 TS=(quasi-random* or quasi random* or pseudo-random* or pseudo random*)
S11 TS=((control or experiment* or conservative) NEAR/5 (treatment or therapy or procedure or manage*))
S12 TS=((singl* or doubl* or tripl* or trebl*) NEAR/5 (blind* or mask*))
S13 TS=(cross-over or cross over or crossover)
S14 TS=(placebo* or sham)
S15 TS=trial
S16 TS=(assign* or allocat*)
S17 TS=controls
S18 #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6
S19 #18 AND #5 AND #4
Search results: 757
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Appendix 8. Web of Science
Search strategy for Web of Science, May 2018
The following indexes Science Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), and Arts &
Humanities Citation Index (A&HCI) within Web of Science were searched from January 2002 to May 2018.
# Query
1 TS=(stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* or cerebral vasc* or cva* or apoplex* or SAH)
Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=2002-2018
2 TS=((brain* or cerebr* or cerebell* or intracran* or intracerebral) NEAR/5 (isch$emi* or infarct* or thrombo* or emboli* or
occlus*))
Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=2002-2018
3 TS=((brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid) NEAR/5 (h?emorrhage* or haematoma* or
hematoma* or bleed*))
Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=2002-2018
4 #3 OR #2 OR #1
Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=2002-2018
5 TS=(emotion* or laugh* or cry* or weep* or tearful* or pseudobulbar affect)
Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=2002-2018
6 TS=(random* or RCT or RCTs)
Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=2002-2018
7 TS=(controlled NEAR/5 (trial* or stud*))
Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=2002-2018
8 TS=(clinical* NEAR/5 trial*)
Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=2002-2018
9 TS=((control or treatment or experiment* or intervention) NEAR/5 (group* or subject* or patient*))
Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=2002-2018
10 TS=(quasi-random* or quasi random* or pseudo-random* or pseudo random*)
Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=2002-2018
11 TS=((control or experiment* or conservative) NEAR/5 (treatment or therapy or procedure or manage*))
Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=2002-2018
12 TS=((singl* or doubl* or tripl* or trebl*) NEAR/5 (blind* or mask*))
Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=2002-2018
13 TS=(cross-over or cross over or crossover)
Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=2002-2018
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(Continued)
14 TS=(placebo* or sham)
Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=2002-2018
15 TS=trial
Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=2002-2018
16 TS=(assign* or allocat*)
Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=2002-2018
17 TS=controls
Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=2002-2018
18 #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6
Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=2002-2018
19 #18 AND #5 AND #4
Indexes=SCI-EXPANDED, SSCI, A&HCI Timespan=2002-2018
Search results: 345
Appendix 9. Other resources
Additional searches
We searched the following conference abstracts and proceedings.
• European Stroke Conference (2011 to 2018)
• Stroke Society of Australasia Annual Scientific Meetings (2011 to 2017)
• World Stroke Congress (2000 to 2016)
• Asia Pacific Stroke Conference (2011 to 2017)
We also searched online clinical trials and research registers in May 2008.
• www.ClinicalTrials.gov ( clinicaltrials.gov/)
(emotion OR laughing OR cry OR weep OR tearful OR pseudobulbar affect ) AND Intracranial Hemorrhages OR Carotid Artery
Diseases OR Brain Ischemia OR Cerebral Hemorrhage OR Cerebrovascular Disorders OR Stroke [DISEASE] = 153
• WHO International Clinical Trials Registry Platform ( who.int/ictrp/search/en/)
Title: (stroke AND emotion OR stroke AND laughing OR stroke AND cry OR stroke AND weep OR stroke AND tearful OR stroke
AND pseudobulbar affect) = 41
ProQuest Dissertations and Theses Database was also searched on May 2018 = 364
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WH A T ’ S N E W
Date Event Description
22 October 2018 New citation required but conclusions have not
changed
Conclusions not changed
14 May 2018 New search has been performed The searches and risk of bias tables have been updated
and a GRADE table added. We found no new trials
for inclusion, so the total number of included studies
remains at seven, with 239 participants. Two trials were
of cross-over design andoutcomedatawere not available
from the first phase (precross-over) in an appropriate
format for inclusion as a parallel randomised controlled
trial (RCT). Thus, the results of the review were based
on five trials with 213 participants. One trial appears to
meet the inclusion criteria for the review, but data are
not available in a format suitable for including in the
analyses (Kim 2017a).
H I S T O R Y
Protocol first published: Issue 3, 2002
Review first published: Issue 2, 2004
Date Event Description
25 September 2009 New citation required but conclusions have not
changed
The first author has changed and there is also a new
author for this version of the review
20 August 2009 New search has been performed This is a substantive amendment. The searches have
been updated. Two new trials have been added, mak-
ing a total of seven trials with 239 participants. Two
trials appear to meet the review inclusion criteria but
information is not available in a format suitable for
pooling. Three further trials have been excluded
14 April 2008 Amended Converted to new review format.
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C O N T R I B U T I O N S O F A U T H O R S
SA: contributed to writing the review. Completed title screening and inclusion/exclusion review, extracted any additional data needed
and updated the risk of bias and ’Summary of findings’ table
KP: screened titles and abstracts for the current update
AH: contributed to writing the protocol and reviewed each version of this review
MH: contributed to writing the review. Completed title/abstract screening, extracted data and oversaw each version of this review
D E C L A R A T I O N S O F I N T E R E S T
SA: none known
KP: none known
AH: none known
MH: none known
S O U R C E S O F S U P P O R T
Internal sources
• The George Institute for Global Health, Australia.
External sources
• Stroke Society of Australasia, Overseas Study Scholarship, Australia.
• Academic Unit of Psychiatry, University of Leeds, UK.
• Division of Clinical Neurosciences, University of Edinburgh, UK.
• Clinical Trials Research Unit, University of Auckland, New Zealand.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
There were methodological changes to the protocol and the review. We split the sensitivity analysis section into Subgroup analysis and
investigation of heterogeneity and Sensitivity analysis.
For all dichotomous outcomes, we changed odds ratios (ORs) with 95% confidence intervals (CIs) to risk ratios (RRs) with 95% CIs
(see Data and analyses).
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Affective Symptoms [∗drug therapy]; Antidepressive Agents [∗therapeutic use]; Crying [∗psychology]; Laughter [∗psychology]; Ran-
domized Controlled Trials as Topic; Stroke [∗psychology]
MeSH check words
Humans
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